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 Cardiotoxicity was investigated in rats challenged with an organophosphorus 
chemical warfare nerve agent VX, S-(2-diisopropylaminoethyl)-O-ethylmethyl 
phosphonothiolate. A paucity of literature on chronic low dose VX challenges and 
electrocardiographic investigations in VX exposure necessitate the need for research 
in the respective areas. Three groups of rats followed three different dosing protocols 
and various organs in addition to cardiac tissues were examined for histopathological 
changes. Cardiotoxicity was determined by electrocardiography studies as well. 
Assays for acetylcholinesterase activity were performed to determine the level of 
enzyme inhibition due to VX.  
 
 Acute single doses of 1.6 LD50 VX were injected subcutaneously into rats 
which received treatment drugs namely pyridostigmine bromide, atropine methyl 
nitrate and pralidoxime chloride to ensure survival. All animals presented tonic-clonic 
convulsions. Light microscopic observations of the cardiac muscles revealed severe 
myocardial damage such as mononuclear cellular infiltration, myofibre degeneration 
and necrosis in all of the VX-challenged rats. However, morphological changes in 
other organs were minimal.  
 
 In the group of rats that received acute dosages of 1 LD50 VX in the absence 
of drug treatment, light microscopy examinations were carried out on day 1, 2, 5, 9 
and 14 following intoxication to capture the time profile of the appearance of organ 
 VIII 
damages. The degree of myocardial degeneration and necrosis were moderate up to 
day 5 and reparation of the cardiac lesions was detected as early as day 9 post-
exposure.  Myocardial lesions were rarely observed on day 14 post-intoxication. As in 
the 1.6 LD50 VX group, injuries in other organs were infrequently observed. 
Electrocardiography recordings revealed QTc and PR interval prolongations in 
addition to abnormalities in cardiac rhythm (atrioventricular blocks, arrhythmias and 
‘Torsade de pointes’ ventriclar tachycardia) in the intoxicated rats. The 
electrocardiographic irregularities were detected up to day 14 post-injection. 
 
 In the third dosing regimen, chronic low doses (0.4 LD50) of VX were 
administered subcutaneously daily up to 8 days. Clinical symptoms of nerve agent 
intoxication started appearing from the fourth day of injection.  The rats were 
perfused for histologic evaluations 24 hours after designated dosing days (dosing day 
1, 3, 4 and 8). Histopathological studies revealed the presence of myocardial damage 
on the fourth and eighth days of dosing. Histopathological changes in other organs 
were uncommon. Electrocardiography measurements demonstrated cardiac 
arrhythmias as early as the second day of dosing, before the appearance of clinical 
symptoms specific for nerve agent intoxication. Significant lengthening of QTc and 
PR intervals was evident from the first day of injection. The aberrations in cardiac 
rhythm and QTc prolongations were reproducible up to 5 days after the last dosing 
day i.e. dosing day 8. This is a novel finding in the research of cardiac toxicity of 
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CHAPTER ONE  INTRODUCTION 
 
 
1.1 CHEMICAL WARFARE NERVE AGENT 
1.1.1 Introduction 
 
Nerve agents belong to a diverse group of phosphorus-containing organic 
chemicals known as organophosphorous compounds. Organophosphorous 
compounds include insecticides such as malathion, ophthalmic agents and 
antihelmintics. The organophosphorous compounds were synthesized in the early 
1800s when Jean Lassaigne esterified phosphoric acid with alcohol. Shortly thereafter 
in 1854, Philip de Clermount reported the synthesis of tetraethyl pyrophosphate at a 
meeting of the French Academy of Sciences. Eighty years later, Dr Gerhard Schrader, 
a German chemist in the I. G. Farbenindustrie laboratory in Leverkusen, investigated 
the use of organophosphorous compounds as insecticides. The use of 
organophosphorous compounds as insecticides was barred by the German military 
and an arsenal of chemical warfare nerve agents was subsequently developed. During 
World War II, in 1941, organophosphorous compounds were reintroduced worldwide 
for pesticide use (Aaron and Howland, 1990).  
 
Grouped into two main classes, G-series nerve agents are the precursors of the 
V-series nerve agents. The members of the two classes share similar properties, and 
are given both a common name and a two-character North Atlantic Treaty 
Organisation (NATO) identifier. Synthesized by a group of German scientists led by 
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Dr Gerhard Schrader, there are four members in the G-series. The first nerve agent 
synthesized was tabun (GA) in 1936. Sarin (GB) was discovered next in 1938, 
followed by soman (GD) in 1944 and finally the cyclosarin (GF) in 1949 (Arnold, 
2004).  
 
The V-series is the second family of nerve agents which coincidentally also 
consists of four members: VE, VG, VM and VX. It has been established that the V-
series nerve agents are approximately ten times higher in toxicity than the G-agent 
sarin (Benitez et al., 2004). S-(2-diisopropylaminoethyl)-O-ethylmethyl 
phosphonothiolate (VX), invented in the 1950s at Porton Down in the United 
Kingdom, is the agent in the V-series family that is most researched upon. The other 
agents in the family have not been studied extensively and current literature on them 
is scarce. 
 
The nerve agents are classified as chemical weapons of mass destruction by 
the United Nations according to UN Resolution 687. Production and stockpiling of 
the agents was outlawed by the Chemical Weapons Convention of 1993 with the 
Chemical Weapons Convention officially taking effect on April 29, 1997 (Paxman 






1.1.2 Incidents of nerve agent use 
 
Despite being synthesised during World War II as chemical warfare agents, 
the nerve agents have not yet been utilised extensively in warfare. Few incidents 
where nerve agents have been employed can be cited, such as in the Iran-Iraq war 
from 1981 to 1988 where nerve agents were used, among other chemical weapons. In 
addition, 5000 Iraqi Kurds were killed when Iraqis exposed the Kurdish village of 
Halabja to nerve agents (Benitez et al., 2004).  
 
However, incidents of poisoning arising from other organophosphate 
compounds such as insectides are more common, whether they are suicidal or 
accidental events. An example is the Jamaican ginger palsy incident in 1930 which 
subsequently led to discovery of the mechanism of action of organophosphate 
compounds (Furtado and Chan, 2004). The first nerve gas terrorism occurred in 1994 
in the city of Matsumoto where about 600 of the citizens were exposed to sarin gas 
(Okudera, 2002).  In 1995, sarin was used again in a domestic terrorist attack by a 
religious group Aum Shinrikyo in a Tokyo subway. 
 
1.1.3 Mechanism of action 
 
Typical of organophosphates, nerve agents disrupt the nervous system by 
inhibiting acetylcholinesterase (AChE). AChE functions by hydrolysing and 
inactivating acetylcholine (ACh), a neurotransmitter which mediates 
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neurotransmission in the central nervous system and peripheral nervous system. ACh 
activates two classes of receptors, namely the muscarinic and nicotinic receptors.  
 
Synapses are specialised junctions in the nervous system that relay signals 
between neurons or between neurons and effector organs such as muscles or glands. 
The presynaptic neuron or axon terminal contains neurotransmitter vesicles in which 
the neurotransmitter ACh resides. The neurotransmitter vesicles dock at the 
presynaptic neuron. Upon the arrival of an action potential or electrical impulse at the 
presynaptic neuron, the release of ACh will be triggered. This happens when the 
arriving nerve impulse bring about an influx of calcium ions into the presynaptic cell 
through voltage-gated calcium ion channels. A biochemical cascade is then initiated 
by the calcium ions which eventually results in the fusion of neurotransmitter vesicles 
with the presynaptic membrane, thereby releasing ACh into the synaptic cleft (Kandel 
et al., 2000; Bear et al., 2001).  
 
Fig. 1.1 Events at a neuronal synapse 
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As shown in Fig. 1.1, ACh diffuses across the synaptic cleft to the membrane 
of the postsynaptic cell where it binds to its receptor. This ligand-receptor interaction 
leads to activation of the ACh receptor which initiates an influx of sodium ions into 
the postsynaptic cell. The entry of large amounts of positive ions changes the local 
transmembrane potential of the cell thereby generating depolarisation. The 
depolarisation results in signal transmission in the form of an action potential in the 
postsynaptic cell. After the nerve impulse is sent and propagated, ACh is rapidly 
degraded into choline and acetate by AChE. The choline moiety undergoes uptake 
into the presynaptic cell and is used for re-synthesis of ACh. The hydrolysis of ACh 
regenerates the receptor and renders it active and free for subsequent ligand binding 
(Benitez et al., 2004). Hence, degradation of the neurotransmitter ACh by AChE 
enables the cholinergic neuron to return to its resting state after activation. 
 
The basic mechanism of action of organophosphate poisoning is by AChE 
inhibition. Organophosphates inactivate AChE by phosphorylating a serine hydroxyl 
group at the active site of AChE. Phosphorylation occurs by the loss of an 
organophosphate leaving group and establishment of a covalent bond with AChE 
(Leikin et al., 2002). The covalent bond which the organophosphate compound forms 
with AChE is situated at the active site of the enzyme where acetylcholine normally 
undergoes hydrolysis. Thus, AChE that is bound to organophosphates is incapable of 
breaking down ACh. This leads to continued interaction of ACh with its receptor and 
a build-up of the neurotransmitter. The result is persistent stimulation of ACh 
receptors and continual transmission of nerve impulses.  
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1.1.4 Pathophysiology and effects on organ systems 
 
Acetylcholine binds at the muscarinic receptors and nicotinic receptors. The 
accumulation of acetylcholine at the receptor sites results in excessive cholinergic 
stimulation of both groups of receptors. Muscarinic receptors are located in the 
central nervous system (CNS) and in the peripheral nervous system (PNS) at 
neuroeffector junctions of the parasympathetic portion of the autonomic nervous 
system. Nicotinic receptors are located in the CNS, in the PNS sympathetic and 
parasympathetic ganglia, and in the neuromuscular junctions (Walter et al., 2000). 
The cholinesterase inhibitors act at all these sites in the CNS and PNS. Hence, 
the signs and symptoms caused by nerve agent intoxication consist of nicotinic and 
muscarinic signs and symptoms in both the CNS and PNS (Walter et al., 2000). The 








Table 1.1 Signs and symptoms of nerve agent poisoning (Marrs et al, 1996a) 
 
Peripheral Nervous System 
 
Central Nervous System 
Muscarinic Nicotinic  
Diarrhoea Mydriasis Confusion 
Urination Tachycardia Convulsions 







Emesis Fasciculations  





The extensive distribution of acetylcholinesterase, at both nicotinic and 
muscarinic receptors throughout the PNS and CNS, can result in a variety of signs 
and symptoms of poisoning. Inhibition of AChE may not account for all of the toxic 
effects of nerve agents. These agents also are known to bind directly to nicotinic 
receptors and cardiac muscarinic receptors. They also antagonize gamma-
aminobutyric acid (GABA) neurotransmission and stimulate glutamate N-methyl-d-
aspartate (NMDA) receptors (Marrs et al., 1996a). These latter actions may partly 
mediate nerve agent–induced seizures and CNS neuropathology.  
Early clinical manifestations of nerve agent poisoning are the nicotinic signs 
of intoxication. However, concurrent nicotinic and muscarinic signs and symptoms 
are often present in both the PNS and CNS. In the later course of poisoning, 
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muscarinic signs and symptoms predominate. In severely poisoned cases, nicotinic 
effect of depolarizing neuromuscular blockade, muscarinic PNS effects such as 
bradycardia, and CNS effects such as coma are presented (Walter et al., 2000; 
Furtado and Chan, 2004). Acute respiratory failure is the primary cause of death in 
acute incidents of intoxication. Respiratory failure is caused by increased airway 
resistance due to bronchorrhoea and bronchoconstriction, respiratory muscle 
paralysis, and most importantly, loss of central respiratory drive (Arnold, 2004).  
 
1.1.5 Routes of exposure 
 
The emergence of symptoms and duration of action depend on the nature and 
type of nerve agent, the amount and route of exposure, the mode of action of the 
compound, lipid solubility and rate of metabolic degradation (Sidell and Borak, 
1992). Routes of exposure to nerve agents include inhalation, absorption through the 




The volatility of sarin, soman, tabun and VX at 77°F is 22000 mg/m, 3900 
mg/m, 610 mg/m and 10.5 mg/m respectively (Watson et al., 2004). The G agents are 
volatile liquids at normal ambient temperatures and they are significantly more 
volatile than VX. Consequently, the most common route of exposure with the G 
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agents is inhalation. Inhalation of VX is possible but is much unlikely due to its 
physical property of low vapour pressure. 
Inhalation absorption of a nerve agent takes place within seconds. Exposure to 
low concentrations of nerve agent vapour produces immediate ocular effects, 
rhinorrhoea and possibly dyspnoea. High concentrations of nerve agent vapour results 
in immediate loss of consciousness, convulsions, paralysis, respiratory failure and 
death. This is due to the rapid absorption of nerve agent vapour across the respiratory 
tract which produces maximum inhibition of AChE (Arnold, 2004).  
The effect of inhalational exposure to nerve agent vapour is dependent on the 
nerve agent vapour concentration and the duration of exposure. For comparative 
purposes, the concentration-time function (Ct) is used to describe the amount of a 
nerve gas to which a victim is exposed. This term, expressed as Ct, is the 
concentration in the air (C), in mg/m3, multiplied by the exposure time (t), in minutes. 
The LCt50 is the Ct that kills 50% of exposed victims. ICt50 is the Ct that incapacitates 
50% of the exposed victims. Incapacitation disables or deprives the victims of the 
ability to live normally afterwards. In other words, permanent injury results in 50% of 
the victims in ICt50 as opposed to death being the endpoint in LCt50. MCt50 is the Ct 
that produces miosis in 50% of exposed victims (Marrs et al., 1996b). The table 




Table 1.2 Lethal, incapacitating, and miosis concentration-time products in 









Sarin (GB) 100 75 3 
Soman (GD) 70 Unknown <1 
Tabun (GA) 400 300 2–3 
VX 50 35 0.04 
LCt50, concentration time function that kills 50% of exposed victims;  
ICt50, concentration time function that incapacitates or causes permanent disability in 
50% of exposed victims;  
MCt50, concentration time function that produces miosis in 50% of exposed victims. 
  
 
1.1.5.2 Absorption through skin and mucous membrane 
 
The effect of dermal exposure to liquid nerve agent depends on the anatomic 
site exposed, ambient temperature and dose of nerve agent. Percutaneous absorption 
of nerve agent typically results in localized sweating caused by direct nicotinic effect 
on the skin, followed by muscular fasciculations and weakness. The latter effects are 
due to the agent penetrating into the skin to exert a nicotinic effect on the underlying 
muscle. In moderate dermal exposures, vomiting and diarrhoea may be expected 
(Arnold, 2004).  
The onset of symptoms following most dermal exposures is usually delayed 
up to several hours as percutaneous absorption takes time. However, VX is a 
persistent agent and is well absorbed through the skin after minimal contact time 
(Craig et al., 1977). The dermal LD50 of VX or LCLo, which is the concentration of 
VX that is needed to cause lethality in 50% of people via percutanous exposure, is 
86µg of VX per kg of body weight (Sidell, 1997; Hurlbut and Lloyd, 1999). This 
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translates into an LCLo of approximately 6 mg of VX for a 70 kg adult human. In 
comparison, the dermal LD50 for contact with liquid tabun, sarin, and soman is 




Exposure of nerve agent via ingestion is largely uncommon, except in cases 
where ingestion of droplets occurs from a line or point source spraying device. As in 
dermal exposures, introduction of nerve agents via ingestion have a delayed but 
abrupt onset of signs and symptoms (Benitez et al., 2000).  
 
1.1.6 Chemical properties 
 
The chemical properties of the more commonly reported nerve agents are 







Table 1.3 Chemical properties of nerve agents (Marrs et al, 1996b) 







Sarin (GB) Liquid Colorless Odorless Miscible 297 140.1 
Soman 
(GD) 








7.2% 464 162.1 





Properties are determined at 68°F and an atmospheric pressure of 760 mm Hg (1 
atm). 
 
Nerve agents are liquids at room temperatures and their melting points range 
from −42°C for soman to −39°C for VX (Zorpette and Frank, 1998). Sarin is miscible 
in water and is hydrolyzed by water to produce a relatively nontoxic product resulting 
from removal of fluorine. Soman and tabun are moderately water soluble but readily 
soluble in organic solvents. Tabun is also hydrolyzed by water. VX is the least water 
soluble of all nerve agents at room temperature but is miscible in cold water and 
organic solvents.  
Chemical structure of an organophosphate is shown in Figure 1.1.  
 
Fig. 1.1 General structure of organophosphate (Walter et al., 2000) 
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The rate of reactivity of an organophosphate with acetylcholinesterase and its 
degree of toxicity depend on the compounds that are substituted for the X and two R 
substituents. Extreme toxicity results when strongly electronegative groups such as 
the halides (e.g. chlorine, fluorine), cyanide or thiocyanate are present (Sidell and 
Borak, 1992).  Sarin has the X substituent for thiocyanate. The formula of sarin is 
shown in Figure 1.2.  
 
Fig. 1.2 Molecular structure of sarin (isopropyl methylphosphonofluoridate) 
(Burda et al., 2002) 
The V agents are sulfur-containing organophosphates. Figure 1.3 shows the 








Fig. 1.3 Molecular structure of VX ((O-ethyl-S-2 diisopropylaminoethyl-methyl 





1.1.7 Decontamination and treatment 
 
Nerve agents undergo rapid hydrolysis at alkaline pHs. This hydrolysis is 
exploited for decontamination of nerve agents and decontamination is carried out by 
neutralising the agents with diluted alkaline household bleach (0.5% sodium 
hypochlorite). Alkaline solutions of soap and water are also used to inactivate the 
nerve agents (Arnold, 2004).  
 
Evaluation of nerve agent-poisoned patients depends on the route of exposure 
as well as severity of the clinical condition. Generally, three drugs are used for 
treating intoxicated patients. They are atropine, pralidoxime chloride (2-PAM), and 
diazepam (Shemesh et al., 1988). Depending on the extent and nature of intoxication, 
other therapeutic interventions such as oxygenation or nebulized ipratropium bromide 
may also be used (Sidell and Groff, 1974).  
 
Atropine, an anti-cholinergic, is a competitive antagonist at the muscarinic 
receptors. It antagonises the effects of accumulated acetylcholine at the muscarinic 
sites in the PNS and CNS. However, signals triggered by the acetylcholine at 
nicotinic receptors in the PNS and CNS will not be blocked by atropine. Therefore, 
atropine is a symptomatic antidote for only the muscarinic signs and symptoms of 
nerve agent poisonings and will not relieve fasciculations, flaccid paralysis or 
respiratory arrest caused by neuromuscular blockade at nicotinic receptors of the PNS 
(Burda et al., 2002). The U.S. Office of the Surgeon General recommends a standard 
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maximum single dose of 2 milligrams for adults in cases of nerve agent exposures. 
Repeated administration should be carried out for titration to effect according to 
clinical diagnosis. Titration of dose is achieved with cessation of secretions and 
regain of normal ventilation. A cumulative dose of approximately 10 to 20 mg of 
atropine in the first couple of hours post-exposure is usually administered for 
adequate control of the symptoms. 
 
Pralidoxime chloride (2-PAM) is an oxime and as a reactivator of 
acetylcholinesterase, it regenerates acetylcholinesterase by freeing the inactivated 
enzyme from the nerve agent. The suggested dose of 2-PAM for nerve agent exposure 
is variable and is dependent on the exposure route and the severity of the poisoning. 
The current U.S. Surgeon General recommendation for 2-PAM is a maximum single 
dosage of 30 milligram per kilogram of body weight or 2 grams for a 70 kg adult 
(Marrs et al., 1996a). Higher doses such as 4 g may be employed in cases of severe 
poisoning. Sidell advices a maximum cumulative dose of 2.5 g of 2-PAM over 1 to 
1.5 hrs with additional doses repeated once or twice every 60 to 90 minutes (Sidell, 
1997).  
 
AChE that is reactivated will be capable to metabolise ACh again. 
Administration of 2-PAM after intoxication is time-critical as binding of 
acetylcholinesterase to the nerve agent may become permanent and irreversible with 
time. The phenomenon of irreversible inactivation of acetylcholinesterase is termed 
aging and once acetylcholinesterase has aged, reactivation will not occur. Thus 2-
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PAM will be ineffective. The time for the aging process to take place varies between 
the different nerve agents (Scremin et al., 2003). The acetylcholinesterase aging half-
life of sarin or the time needed for 50% of the sarin-acetylcholinesterase enzyme 
complex to age is approximately 5 hrs. In contrast, the acetylcholinesterase aging 
half-life of soman and VX is about 2 minutes and over 40 hours respectively (Marrs 
et al., 1996a). 
 MARK-I kits (Meridian Medical Technologies, Inc.; Columbia, MD) are 
presently being used in the military. The kits contain 2 mg of atropine and 600 mg of 
2-PAM in spring-loaded auto-injectors. Depending on the severity of exposure, 1 to 3 
kits can be used in field. 
Seizures accompany severe nerve agent intoxications and benzodiazepines are 
used to control the seizure activity. These drugs function by stimulating GABA, the 
main inhibitory neurotransmitter in the CNS. Increased seizure threshold and sedation 
will result with stimulation of GABA (Benitez et al., 2004). Diazepam, a member of 
the benzodiazepine family, is commonly given to severely-poisoned individuals (10 
mg intravenous or orally in adults or 0.2 mg/kg in pediatric patients) to control the 
seizures. Recommended management is based on severity of symptoms. 
 
Pyridostigmine bromide is given as pre-exposure drugs in case of anticipated 
nerve agent exposure (Scremin et al., 2003). Increased chances of survival as well as 
better clinical prognosis are achieved with the use of pyridostigmine bromide together 
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with atropine and 2-PAM when compared to without the pre-treatment drug (Keller et 
al., 1991). The dosage regimen is 30 mg orally every 8 hrs, for up to 7 days.  
 
1.2 EFFECTS OF VX (O-ETHYL-S-2 DIISOPROPYLAMINOETHYL-
METHYL PHOSPHONOTHIOLATE )  AND OTHER NERVE AGENTS 
Effects of nerve agents and organophosphate compounds on organ systems 
particularly the cardiovascular and nervous systems had been studied in rodents and 
primates.  
1.2.1 Histopathological findings 
Histopathologic changes had been described in the brain, heart or/and skeletal 
muscle following challenge to nerve agents such as soman (Singer et al., 1987; Britt 
JO Jr et al., 2000) and sarin (Singer et al., 1987). Studies were done to link and 
correlate these histological observations to physical signs and symptoms of 
poisoning. These studies also aimed to predict the extent of damage in the organs by 
monitoring the severity of clinical signs of poisoning should the correlation between 
histopathological changes and signs of poisoning be established. Biochemical assays 
as well as observations of the physical signs of poisoning were carried out to establish 
the mechanisms by which the damages arose.  
Doses of the chemical warfare nerve agents soman and sarin that resulted in 
convulsions in rats had been proven to cause acute neuronal necrosis (Baron, 1981; 
McLeod et al., 1984). In another study, rats that survived single convulsive doses of 
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either soman or sarin were demonstrated to have cardiac as well as neuronal lesions 
(Singer et al., 1987). It was of high significance as cardiac arrhythmias had been 
reported in many cases of humans poisoned with pesticides and nerve agents 
(Soboleva et al., 1982; Brill et al., 1984).  Light microscopic examinations were 
carried out on the intoxicated animals at time points up to 35 days post exposure. The 
study showed brain lesions in almost all of the rats which underwent convulsions. 
These animals experienced lacrimation, salivation, tremors in addition to the 
convulsive activity. Convulsions had been established as a prerequisite for the genesis 
of large segmental and necrotic neuronal lesions (Lemercier et al., 1983; McLeod et 
al., 1984). Heart lesions occurred in 9 of the 18 animals that had brain lesions that 
arose as a consequence of the convulsions (Singer et al., 1987). Depending on the 
interval between dosing and the day on which the animals were sacrificed, the 
myocardial damage varied in appearance. The damage was most evident in the left 
ventricular myocardium and most severe in the subendocardial region.  
Animals sacrificed on day 2 post-intoxication showed multiple focal areas of 
severe myolysis characterised by loss of cross striations, macrophages infiltration and 
fragmentation as well as shrinkage of fibres of the myocardium (Singer et al., 1987). 
By 9 days post-intoxication, early resolution of necrotic areas were observed. 
Myocardial damage was rarely observed beyond day 14 after the single exposure.  
Histopathologic changes had been reported in the brain, heart and skeletal 
muscle of rhesus macaques ten days after administration of soman (Britt JO Jr et al., 
2000). Although lesions in the brain were not as prevalent as those reported in other 
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studies of primates and rodents, the occurrence of brain lesions correlated 
significantly with convulsions. Nine of the 15 animals that convulsed had brain 
lesions while only 1 out of the 21 animals that did not experience convulsions had 
brain lesions. Neuronal loss in the study occurred mainly in the hippocampus, 
amygdala and thalamus. They included neuronal necrosis, spongiosis, gliosis, 
astrocytosis or an abnormal increase in astrocytes number due to the destruction of 
nearby neurons, and vascularisation. The findings were consistent with previous 
studies of soman toxicity in non human primates which reported necrotizing brain 
lesions in the hippocampus, entorhinal cortex of the temporal lobe, frontal cortex, 
amygdaloid complex and caudate nuclei (Wall et al., 1987; Baze, 1993).  
Cardiomyopathy observed consisted of myocardial degeneration and acute 
cardiac myofibre necrosis with early fibrosis. In contrast to other rodent studies, 
myocardial damage was not significantly associated with neuronal damage with only 
3 animals presenting both brain and heart lesions. Seven animals had only brain 
lesions while 3 had only heart lesions. These findings were in agreement with a 
separate primate study that found animals with neurotoxicity caused by soman but 
without any cardiac lesions (Lallement et al., 1997). Skeletal muscle lesions were 
present in most of the animals, regardless of whether convulsions were present. 
However, these lesions ranged only from minimal to mild in severity. Most of the 
animals with damage in the skeletal muscle had muscular tremors as one of the 
symptoms of intoxication (Britt JO Jr et al., 2000).   
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The relationship between myocardial damage and brain damage had been 
investigated in several studies. Currently, there is controversy over whether 
myocardial damage is related to convulsions and thereby neurogenic in origin. In a 
study in support of the hypothesis that cardiomyopathy is neurogenic, histological 
examinations demonstrated that rats dosed with soman had myocardial lesions that 
correlated significantly with central nervous system lesions that resulted from seizure 
activity (Tryphonas and Clement, 1995). The CNS damage reported was bilaterally 
symmetrical and began with vacuolation of the neuropil. Degeneration of astrocytes 
and neuronal necrosis that culminated in liquefactive necrosis and focal haemorrhage 
subsequently appeared. Common affected target sites were the cerebral cortex, limbic 
system, thalamus and substantia nigra. However, repair in the affected sites was 
observed with reversal of some vacuolation, microgliosis and capillary endothelial 
cell proliferation.  
The myocardial damage started with myocytolysis or focal dissolution of the 
cardiac muscle fibres. At 72 hours, the myocardial damage gradually evolved into 
coagulative myocytolysis of the muscle bundles and later, fibrosis of the affected 
area. The latter was accompanied by transient infiltration of acute inflammatory cells. 
As with other reports (Singer et al., 1987; Britt JO Jr et al., 2000), the left ventricle of 
the heart particularly the subendocardial wall and papillary muscles were noted to be 
most consistently affected.  
Anticonvulsant drug treatment had been utilised to investigate the relationship 
between convulsions and neurological damage with myocardial changes 
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(McDonough et al., 1995). Rats were treated with a number of different compounds 
that either terminate or did not terminate seizures caused by administration of a 
convulsive dose of soman. The three classes of drugs namely anticholinergics 
(scopolamine, atropine, benactyzine, trihexyphenidyl); benzodiazepine (diazepam); 
and NMDA antagonist (MK-801) were given to rats at varying time points of seizure 
activity (2.5, 5, 10, 20 and 40 minutes). Neurological damage was observed in nearly 
all animals (98%) in which the treatments were ineffective in the termination of 
seizure activity. Histological damage was most commonly observed in piriform 
cortex (89%), followed by amygdala (72%), hippocampus (70%), thalamus (55%) 
and cerebral cortex (49%). Histopathological changes included degeneration and 
necrosis of neurons. Shrunken and necrotic neurons and diffused neuropil damage 
were detected as well. This observation of neurological damage in almost all animals 
that convulsed supported the well-established notion that neuropathy was set off by 
convulsive activity. In addition, an important finding about the duration of seizure 
activity needed to produce neural lesions was discovered. The data indicated that a 
minimum duration of approximately 20 minutes of convulsive activity was needed to 
bring about minimal neural damage even when the anticonvulsant treatment was 
successful. Animals with epileptiform activity that was terminated within 10 minutes 
had no neurological damage. An increasing incidence of neurological damage was 
observed when the seizure was ended after 20 minutes (10% of the animals) and 40 
minutes (79% of the animals) of convulsion. Regardless of the type of drug or dose 
that was administered, prevention against the development of neurological damage 
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was simply related with the ability of the drug to bring the seizure to an end ahead of 
the time that was needed for the emergence of damage.  
On the other hand, cardiomyopathy was not related to the effectiveness of the 
drug treatments and appeared at a higher frequency of 88% compared to the 
neurological lesions (57%) in the study (McDonough et al., 1995).  Hence the study 
concluded that the mechanisms responsible for the genesis of cardiac lesions upon 
nerve agent exposure were distinct from that of neurological damage and were clearly 
not neurogenic as reported in other studies (Singer et al., 1987; Tryphonas and 
Clement, 1995). A substantial number of animals that underwent 2.5 to 5 minutes of 
seizure activity before it was terminated by the drugs had cardiac lesions. However, 
practically half of the animals without cardiomyopathy were those in which the drugs 
were unsuccessful in ending the convulsions. Thus it was suggested that seizure 
activity was not likely to have initiated the high incidence of cardiac lesions observed.  
McDonough et al. (1995) also revealed that early treatment with 
anticholinergic drugs was able to protect the animals from cardiomyotoxicity. This 
proposed that the biochemical pathway via which cardiac lesions arose happened 
more rapidly and might progress by the cholinergic mechanism. Hence, the cardiac 
lesions could have been a result of the accumulation of acetylcholine due to inhibition 




1.2.2 Electrocardiographical studies 
Numerous clinical cases had reported sudden cardiac death after nerve agent 
or organophosphate poisoning and arrhythmias were a common finding in many acute 
cases of intoxication (Saadeh et al., 1997; Karki et al., 2004). Although the 
mechanism via which organophosphates bring about cardiotoxicity remains to be 
elucidated, manifestation of the cardiac rhythmic changes had been described 
(Ludomirsky et al., 1982). Rhythm alterations are first presented with a brief increase 
in sympathetic discharge which is subsequently followed by a second phase of intense 
and prolonged parasympathetic tone. A third phase consisting of ventricular 
arrhythmias is also observed in some patients. In this third phase of cardiac toxicity, 
prolongation of the Q-T interval may be accompanied by torsade de pointes 
ventricular tachycardia and eventually, ventricular fibrillation.  
In a report on some 600 victims of the sarin nerve gas terrorism in the city of 
Matsumoto, arrhythmia was one of the symptoms recorded in some victims. The 
irregularity in heart rhythm, together with a decrease in cardiac contraction, were 
noted in addition to general symptoms of sarin poisoning such as decreased visual 
acuity with marked miosis, headache, low grade fever and extremities becoming 
insensitive to touch (Okudera, 2002).  
In a follow-up examination of a severely-intoxicated patient one year after 
exposure in the Matsumoto terrorism incident, Sekijima et al. (1995) described 
epileptic discharges in electroencephalogram (EEG) recordings during sleep and 
frequent premature ventricular contractions (PVC) in Holter electrocardiograms of 
 25 
the patient. This happened despite the patient’s erythrocyte acetylcholinesterase level 
being normalised three months after exposure. It signified the presence of residual 
adverse effects of nerve gas poisoning on the nervous and cardiac systems. 4.7 and 
5.5% of the victims experienced lasting symptoms associated with sarin exposure 
including asthenia, shoulder stiffness, fatigue of the eyes and blurred vision in two 
separate cohort studies one and three years after the nerve gas attack respectively 
(Nakajima, 1999). They were suggested to be after effects or sequelae related to sarin 
poisoning. Victims who had these symptoms one year after the attack were those who 
had lower erythrocyte cholinesterase activity profiles right after the sarin attack. The 
reports demonstrate that consequences of nerve agent intoxication are far-reaching 
and persistent even years after the exposure.   
The widespread use of organophosphorus compounds as agricultural 
insecticides had resulted in many incidents of organophosphate poisoning arising 
from occupational exposure, accidental or suicidal inhalation and ingestion 
(Jeyaratnam, 1990). In an article evaluating 46 patients admitted to the medical 
intensive care unit as a result of acute poisoning with organophosphate or carbamate, 
cardiac complications were detected in 31 (67%) patients (Saadeh et al., 1997). The 
patients, admitted over a five year period, had various cardiac changes: cardiac 
arrhythmias (24%), non-cardiogenic pulmonary edema (43%) and abnormalities in 
electrocardiography such as prolonged QT interval (67%), elevated ST segment 
(41%) and conduction defects (9%). Despite the occurrence of prolonged QT interval 
in 67% of the patients, there was no polymorphic ventricular tachycardia of the 
torsade de pointes type observed among these patients. Torsades de pointes, 
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frequently associated with a prolonged QT interval, is a life-threatening arrhythmia 
that has a unique undulating, spindle pattern in which the QRS peaks first appear to 
be up and then to be down. However, ventricular fibrillation appeared in 2 patients 
which resulted in a mortality of 4%. Sinus tachycardia (35%), sinus bradycardia 
(28%) as well as hypertension (22%) and hypotension (17%) were also reported. 17% 
required respiratory assistance due to central respiratory depression. The cardiac 
complications were suggested by the authors to have been caused by increased 
sympathetic and parasympathetic tone, hypoxaemia, acidosis and derangements in 
electrolyte constitution.  
In another hospital report of 37 patients admitted over a period of three years 
due to similar consequence of acute organophosphate or carbamate exposure, nearly 
the same forms of cardiac aberrations as that reported by Saadeh et al. were 
documented (Karki et al., 2004). Although about a similar percentage (62.2%) 
developed cardiac toxicity, only 37.8% had prolonged QTc interval in this study. 
However, one of these patients with QTc prolongations developed torsade de pointes 
ventricular tachycardia, as compared to none in patients observed with QTc 
prolongations in the previous five year study. 
Comprehensive and detailed electrocardiographic studies following nerve 
agent exposure are few and one such study revealed cardiac abnormalities in rats 
following challenges to single high doses of VX (Robineau, 1987a). Rats 
anaesthetised with pentobarbital were subcutaneously injected with 12µg/ml or 0.76 
LD50 of VX. The LD50 in the study was established at 15.8 ± 2.0 µg/kg of body 
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weight. The 0.76 LD50 dose was chosen on the basis that sufficient clinical symptoms 
of intoxication could be produced without causing lethality. Electrocardiography 
measurements were made every 5 minutes for 30 seconds over a period of 150 
minutes. 56.5% of the VX-intoxicated rats showed cardiac arrhythmias and isolated 
extrasystoles. The high incidence of abnormal cardiac rhythm in the VX-treated rats 
was significantly greater compared to the incidence in the control group (19%). The 
occurrence of irregular cardiac rhythm in the control group was suggested by the 
authors to be attributed to the anaesthetic procedure.  
Serum nonesterified fatty acid (NEFA) levels were observed to rise in 
organophosphate-intoxicated patients presenting with arrhythmias (Karagueuzian et 
al., 1982). In the same study, elevated plasma NEFA concentrations in VX-exposed 
rats further supported the hypothesis that cardiac rhythm irregularities were a 
consequence of cardiotoxicity caused by VX.  
The cardiac arrhythmias appeared as early as 50 minutes post injection and 
continued for the period of 150 minutes of recording. This was an important 
discovery since documented clinical cases reported the appearance of cardiac 
abnormalities a few hours or even few days after the organophosphate exposure (Kiss 
and Fazekas, 1979; Ludomirsky et al., 1982).  
Another finding was that the death rate was found to correlate with the 
occurrence of cardiac arrhythmias, with the frequency of mortality increasing with 
abnormal cardiac rhythm. Only 20% of the exposed rats which did not show 
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abnormal cardiac rhythm died in contrast to the high death rate of 60% in rats which 
showed cardiac arrhythmias.  
In an another study of the effects of VX on electrophysiology and heart 
rhythm in dogs, beagle dogs were subcutaneously administered with 1.5, 3.0 or 6.0 
µg/kg body weight of VX i.e. 0.25, 0.5 or 1 LD50 of VX (Robineau and Guittin, 
1987b). The group which received 0.25 LD50 VX was not notably different from the 
controls. In conscious or anaesthetised dogs treated with 0.5 LD50 VX, the mean 
arterial pressure decreased to some extent and the QT interval in the ECG tracings 
increased. These parameters were further augmented in dogs which received 1 LD50 
VX. Additionally, a decline in left ventricular performance and contraction capacity 
as well as an extended PR interval was found in the 1 LD50 group.  
Cardiac rhythms in 0.5 LD50 and 1 LD50 VX-treated groups were considerably 
altered compared to the control group. Observations included sinus bradycardia, first 
degree atrioventricular block and ventricular premature complexes. Polymorphous 
ventricular tachycardia of the torsade de pointes form was additionally noticed in one 
of the 1 LD50 VX-treated dogs which eventually died.  
 
1.3 AIMS AND SIGNIFICANCE OF PRESENT STUDY 
Most studies and reports of nerve agent poisoning have focused on exploring 
the acute histopathological damages these agents have on the biological systems by 
utilising high convulsive doses in the challenges. When high lethal doses were used, 
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treatments using atropine and 2-PAM were usually administered to ensure animal 
survival (Tryphonas and Clement, 1995; Britt et al., 2000). Although the possibility 
of the treatments themselves causing organ damages is ruled out with the use of 
treatment controls serving as points of reference, one cannot say the same for the 
degree of interference that the medications may have on the physical manifestation of 
the histopathological injury or the time taken for these impairments to appear after the 
exposure.  
 
With acute high nerve agent dosage challenge studies revealing the presence 
of cardiotoxicity, the present study aims to investigate possible cardiac toxicity in 
continual exposure of low doses of nerve agent VX. Similar to other nerve agents, the 
effects of VX are cumulative and chronic exposure to low amounts could direct 
towards ultimate serious intoxication. If toxic effects were indeed conclusive from 
repeated challenges to low doses of nerve agent, it will be justifiable to determine a 
no-adverse-effects-level dose for VX exposure. This particular dose will be useful for 
deciding whether an incident site is suitable for reopening to the public as well as 
determining the safety zones around such a VX-contaminated area.  
 
Clinical records have revealed that delayed cardiac toxicity is evident in 
humans who were acutely exposed to nerve agents and other organophosphates 
(Sekijima et al., 1995). The belated cardiotoxicity occurred in spite of therapeutic 
medication being given at the initial stages of intoxication and with the normalisation 
of acetylcholinesterase level three months after exposure. Hence, it is vital to 
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investigate for such delayed toxicity in the cardiac system following nerve agent 
exposure.  
 
Not only has there been a scarcity of toxicity and histological studies on 
chronic nerve agent poisoning, electrocardiography reports on both acute and chronic 
nerve agent poisoning is also limited. It is especially true for ECG studies on chronic 
low level exposure with almost no published reports thus far.  
 
Hence, in this study, various subject matters will be investigated upon. The 
objectives of the present study are: 
1) To examine the types of histopathological damages in different organs from 
experimental animals that appear in cases of acute intoxication without the use 
of treatments. 
2) To establish the time profile needed for the appearance and possible resolution 
of these damages if they are indeed reparative. 
3) To explore the association between cardiac damage and convulsions. 
4) Investigation of toxic symptoms and histological injuries following repeated 
exposures to low levels of VX. 
5) To determine if anticholinergic drugs are capable of protecting the heart from 
acute exposure as suggested by some studies (McDonough et al., 1995). 
6) Detection of the types of cardiac arrhythmias in acutely poisoned animals and if 
the rhythm aberrations are persistent. 
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7) To investigate if cardiotoxicity manifested in the form of irregularities in 
cardiac rhythm is present in chronic low dose VX exposure. 



































CHAPTER TWO  MATERIALS AND METHODS 
 
2.1 SUPPLY OF NERVE AGENT VX 
  
 Nerve agent VX was synthesised in Centre for Chemical Defence of DSO 
National Laboratories, Singapore. 
 
2.2 CHEMICALS AND EQUIPMENTS 
 
Chemicals for toxicology study 
 Pyridostigmine bromide and atropine methyl nitrate (AMN) were purchased 
from Sigma Aldrich (Steinheim, Germany). Pralidoxime chloride or 2-
pyridinealdoxime methochloride (2-PAM) was from Aldrich Chemical Company Inc. 
(USA). Sodium chloride was bought from MERCK (Darmstadt, Germany). Sodium 
hypochlorite or bleach (10-12%) was purchased from Sino Chemical Company Pte 
Ltd. (Singapore). Water was purified with a Milli-Q system purchased from Millipore 
(USA). 
 
Materials for biochemical study 
 Chemicals sodium hydrogen phosphate, sodium dihydrogen phosphate, 
methanol and hydrochloric acid were purchased from MERCK (Darmstadt, Germany) 
while ethopropazine, 4,4’-dithiodipyridine and triton X-100 were obtained from 
Sigma Aldrich (Steinheim, Germany). Acetylthiocholine iodide was purchased from 
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Sigma Chemical Company (St. Louis, USA). Molecular microplate 
spectrophotometer system Spectra Max 250 was purchased from Research 
Instruments (Singapore). Elecsys® 2010 immunoanalyser was manufactured by 
Roche Diagnostics (Basel, Switzerland).  
 
Materials for surgery and post surgical care 
 Hypnorm, constituted of fentanyl citrate (0.315 mg/ml) and fluanisone (10 
mg/ml), was acquired from Jansesen Pharmaceutica (Beerse, Belgium). Midazolam 
was purchased from La Roche Ltd (Basel, Switzerland). Isoflurane was from Rhodia 
Organique Fine Ltd (Bristol, UK) while the isoflurane vaporiser was a product of 
MPB Industries (Kent, England). The gas scavenging device Fluovac® was bought 
from Shirley Aldred and Co. Ltd (Bradwell, England). Mixture gas (5% CO2 in 95% 
O2) was ordered from National Oxygen Pte Ltd (Singapore). 
  
 Suture and tissue adhesive glue or Histoacryl® were products of Aesculap AG 
Co. KG (Melsungen, Germany). Buprenorphine hydrochloride was from Schering-
Plough (Singapore). Glutaraldehyde solution (25%), ampicillin and glucose were 
purchased from Sigma-Aldrich Pte Ltd (Singapore).  
 
Chemicals for morphological study 




Equipments for electrocardiographical measurements 
TSE telemetry system was purchased from Technical and Scientific 
Equipment GmbH (Germany). 
 
2.3 ANIMALS 
 Female Sprague-Dawley rats (160-180 g) were obtained from Animal 
Resource Centre, Australia. Upon arrival, the animals were acclimatised and 
quarantined for a week to be tested for any signs of diseases. After acclimatisation, 
the animals were housed in polycarbonate cages at ambient conditions at controlled 
temperature (22 ± 2 °C) and humidity (60% ± 10%). A 12-hour light dark cycle was 
maintained in the animal holding room. Standard rodent pellets and water were 
available to the rats ad libitum. The animals weighed 211.27 ± 2.05 g at the start of 
the experiments. A total of 60 animals were used in the study with 10 serving as 
experimental controls. The animals were treated according to the NACLAR 
Guidelines on the Care and Use of Animals for Scientific Purposes (NACLAR, 
2004).  
 
2.4 BIOCHEMICAL ANALYSIS 
 
 Prior to toxicology studies, blood samples were collected from the tail vein of 
each animal for determination of pre-exposure AChE activity and creatine kinase – 
MB (CK-MB) level. Blood was again drawn at various durations following VX 
exposure to be assayed for post-exposure AChE and CK-MB levels. For 
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acetylcholinesterase assay, 20 µl of whole blood was collected in heparinised tubes to 
prevent blood clotting and frozen at -80 °C until determination. Blood intended for 
CK-MB analysis (600 µl) was collected in tubes with no preservatives, allowed to 
clot, centrifuged and the plasma kept frozen at -40 °C until analysed.  
 
2.4.1 Acetylcholinesterase assay 
 
 Blood AChE activity was determined by a modified method of Ellman et al. 
(1961) developed by Augustinsson et al. (1978) which allowed specific chemical 
analysis of the enzymatic activity in whole blood samples. 0.1 M phosphate buffer 
(pH 7.4), prepared with sodium hydrogen phosphate and sodium dihydrogen 
phosphate, was used both in the preparation of the reagents and as a diluent. Whole 
blood was thawed in ice-filled insulated boxes and diluted down forty times in triton 
X-100 of 0.03% (v/v). The diluted blood was first pippetted into wells. Addition of 
ethopropazine (0.06 mM) and 4,4’-dithiodipyridine (0.5 mM) solution mixture 
followed, after which a ten minute incubation period was allowed for the inhibition of 
plasma butyrylcholinesterase by ethopropazine. AChE substrate acetylthiocholine 
iodide (1.125 mM) was subsequently added after the ten minute incubation. The 
enzymatic reaction of erythrocyte AChE was read at 324 nm and measurement of 
haemoglobin was determined at its absorption maximum of 450 nm. AChE activity, 
expressed in units per gram haemoglobin, was then computed after normalisation of 
the enzyme activity with haemoglobin.  
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2.4.2 Creatine kinase – MB test 
 
  Quantity of CK-MB was measured via chemiluminescent immunoassay using 
Elecsys® 2010 immunoanalyser and the values of CK-MB mass were given in µg/l.  
 
2.5 INJECTION OF NERVE AGENT VX AND DRUG TREATMENT 
 
Pure VX was diluted in sterile saline to the desired concentration in a 
sterilised setting. The LD50 of VX was determined to be 16.25µg per kg of body 
weight through in-house testing by DSO National Laboratories which was conducted 
under tightly-secured and stringent conditions. A 25 gauge 1 inch needle was used for 
the subcutaneous injection of the nerve agent in the lateral-ventral region of the 
animal i.e. at the side of the animal’s body between the thoracic and abdominal area. 
The subcutaneous injection of VX was performed by pinching a bit of skin between 
the fingers to form a fold and the needle was inserted into the skin at the bottom of 
the fold where the loose skin meets the body.  Normal sterile saline was injected into 
control animals. 
 
Treatment drugs were given to animal models receiving 1.6 LD50 VX. 
Pyridostigmine bromide, atropine methyl nitrate and pralidoxime chloride were all 
dissolved in sterile 0.9% saline. The concentration of pyridostigmine bromide made 
was 0.26 mg/ml while the concentration of atropine methyl nitrate and pralidoxime 
chloride were finalised at 4 mg/ml and 50 mg/ml respectively. The concentrations 
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were chosen in consideration of the body weights of the animals which consequently 
determined the volume of solutions to be injected into the animals.  
 
Injection of pre-treatment drug pyridostigmine bromide solution (0.13 mg per 
kg of body weight) was carried out 30 minutes prior to VX delivery. Post treatment 
drugs atropine methyl nitrate (2 mg per kg of body weight) and pralidoxime chloride 
(25 mg per kg of body weight) were injected separately straight after the 
administration of VX. Delivery of all three treatment drugs were done via the 
intramuscular route into the gastrocnemius muscle of the animal. Injections of the 




2.6 ACUTE AND CHRONIC VX EXPOSURE PROTOCOLS AND 
OBSERVATION OF CLINICAL SIGNS AND SYMPTOMS OF 
INTOXICATION  
 A total of three dosing regimens were followed in this study. The animals 
were weighed prior to injection for calculation of the amount of VX or saline solution 
to be given. Table 2.1 displays the number of animals used in the first two dosing 
protocols in which animals were challenged with single high doses of VX. Table 2.2 
presents the number of animals used in the third dosing regimen. In all the three 
exposure protocols, the animals were returned into their respective cages following 
injection of VX. Observation for clinical manifestation of toxic signs and symptoms 
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was conducted for up to two hours post-exposure. Due to the nature of chemical that 
was being dealt with and the risk involved, the number of animals used for the 
experiments had been kept to the minimum. 
 In the first regimen, a single dose of acute 1.6 LD50 VX was carried out to 
ascertain the maximum amount of histological damage that could possibly be caused 
by VX. Three drugs - pyridostigmine bromide, atropine methyl nitrate and 
pralidoxime chloride were administered to the rats to ensure survival. Animals 
serving as treatment controls received the three drugs in the same sequence. Saline 
solution was injected into the treatment controls in place of VX. Perfusion of the 
animals was performed 24 hours after intoxication for histopathological assessment 
by light microscopy. 
 
 In the second dosing routine, the animals were subjected to a single acute dose 
of 1 LD50 VX. No drug treatment was given to the animals. Monitoring of the weights 
of the animals and observation for signs of nerve agent poisoning was carried out 
daily up to 14 days after exposure. The intoxicated animals were sacrificed on 
selected days post-exposure to correlate the time profile to histopathological damages 
in the organs. As shown in table 2.1, the days chosen for perfusion of the animals 
were 1 day, 2 days, 5 days, 9 days and 14 days post VX exposure.  
 
 In the third dosing regimen, the animals were repeatedly injected on a daily 
basis with a low dose of 0.4 LD50 VX up to a maximum of 8 days. The chronic 
repeated injections were conducted on a five day Monday through Friday injection 
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regimen. The animals in this group received no treatment therapy too. The rats were 
perfused on different days of VX dosing to determine the amount of doses needed for 
histopathological changes in the organs to take place. Table 2.2 displays the selected 
days for histopathological investigations i.e. dosing days 1, 3, 4 and 8. The animals 
were perfused 24 hours after the designated final dose. Recording of the weights of 
the animals as well as observation for symptoms after injections were made daily 
until the day of perfusion.  
 
Table 2.1 Number of animals used in the two acute dosing protocols 
  
               No. of days post injection on which perfusion was performed 
VX (LD50)      Day 1       Day 2       Day 5        Day 9        Day 14 No. of 
controls 
1.6         4 3 
1         4              4               4                4                 6 4 
     
 
Table 2.2 Number of animals used in the chronic dosing regimen 
 
     No. of days of dosing 
VX (LD50)          1 day           3 days          4 days             8 days     No. of 
controls 




2.7 ELECTROCARDIOGRAPHICAL STUDIES 
 
2.7.1 Telemetry system 
 
 The Technical and Scientific Equipment (TSE) telemetry system used in this 
study was designed for the recording of physiological parameters of small laboratory 
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animals. Radiotelemetry is based on the wireless transmission of data by 
electromagnetic waves, known more generally as radio waves. The system consisted 
of  
• Transmitter with integrated battery and antenna 
• Receiver with receiving antenna which was specifically assigned to each 
transmitter 
• Control unit (decoder) for decoding of the analogue transmitter signals 
• Computer system with data acquisition and analysis software program 
 
2.7.2 Physiological parameters and calibration values 
 
 The physiological parameters or signals measured using TSE telemetry 
system were ECG signals and body temperature. The temperature sensor was directly 
integrated into the transmitter and therefore the displayed temperature was the 
temperature inside the body of the animal. In addition to ECG and temperature, the 
system measured heart rate of the animal indirectly by deriving values from the ECG 
signals.  
 
 Calibration values of the ECG and temperature varied for different sets of 
transmitters and the values needed to be re-entered into the recording software 
programme in the event when a different transmitter was used. 
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2.7.3 Implantation of electrocardiography transmitter 
 
 The transmitter device or telemeter was a small device equipped with 
electrodes or leads for the measurement of ECG. Since telemetric recording of the 
physiological data was wireless, the transmitter was implanted inside the animal 
body. Fig. 2.1 shows the transmitter, a small 2 cm by 1 cm device consisting of a 








2.7.3.1 Surgical procedure 
 
 On the day prior to the surgery, all surgical tools and gauze were autoclaved 
to ensure sterility. The transmitters were soaked in 2% glutaraldehyde solution for a 
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minimum of two hours before rinsing and stored in sterile saline solution half an hour 
ahead of the surgical procedure. 
 
Anaesthesia of the animals was induced by placing the animal into an 
isoflurane induction chamber. The chamber was supplied with a stable stream of 5% 
isoflurane vapour from the isoflurane vaporiser. Oxygen cylinder containing mixture 
gas consisting of 5% CO2 and 95% O2 was delivered together with the anaesthetic gas 
agent. The oxygen flow meter was set to 1 litre per minute. The gas scavenging hood 
was switched on throughout the entire procedure to scavenge any anaesthetic gas.  
 
Once the animal displayed loss of its righting reflex and entered deep sleep, 
the gas scavenging system and vaporiser connections was switched to the face mask 
or nose cone. The rat was transferred from the chamber to the operating table with its 
nose in the face mask. Reduction of the vaporiser setting was then done to maintain a 
flow rate of 1.5-3% isoflurane vapour in the face mask. This isoflurane concentration 
was generally used for maintenance of anaesthesia (Flecknell, 1996). The 
maintenance concentration was adjusted slightly as rats vary to some extent in their 
response to the anaesthetic agent.  
 
Fur was carefully shaved in the surgical areas and the surgical sites were 
scrubbed with surgical scrub Hibiscrub®. With the use of a sterile technique, the 
intraperitoneal implantation of the TSE transmitter began by making an incision in 
the abdomen. The transmitter was implanted in the peritoneal cavity and sutured to 
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the folds of the abdominal membrane. The suture used was size 4/0, braided silk, 
coated and non-absorbable. Two tunnels under the skin were made in opposite 
directions to convey the two ECG leads of the transmitter which were subsequently 
sutured onto the muscles. The white-coloured positive lead was embedded and 
sutured in the right spinotrapezius located across the right dorsal thoracic region of 
the rat. The blue-coloured ground lead was embedded and sutured in the left region of 
the internal oblique adjacent to the biceps femoris. The positions of the leads and 
location of the embedded transmitter device are presented in Fig. 2.2. Since the 
placement of the leads was critical and needed to be precise for ECG signal detection, 
the usage of non-absorbable suture was necessary for sewing in the abdominal and 




                            
Fig. 2.2 Placement of the transmitter body and positions of the positive 
and ground lead in a rat model 
 
 The abdominal membrane was stitched up enclosing the transmitter device in 
the peritoneal cavity and all skin incisions that were made were closed with sterile 
surgical clips to aid healing. 
 
 Upon completion of the surgical procedure, the animal was subcutaneously 
injected with buprenorphine hydrochloride (0.05mg/kg) and ampicillin (150mg/kg). 5 
ml of 5% glucose solution was also given via the intraperitoneal route. The animal 
was placed in an incubator with an optimum temperature of 37 °C. Upon full 
recovery of consciousness, the animal was returned to its original cage.  
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2.7.3.2 Post-operative regimen 
 
 Post-surgery care involved close monitoring of body weight. Buprenorphine 
hydrochloride (0.05mg/kg) and ampicillin (150mg/kg) were given for a period of 5 
days post-surgery (Kilpelainen and Martio, 1992). Observation and monitoring of the 
operated animal was done to look out for any signs of pain or distress such as 
abnormal hunched posture, anorexia and guarding etc. 5% glucose was given should 
there be a loss in body weight of 3-4%. If poor wound healing occurred as a result of 
the animal removing the surgical clips, the animal was anaesthesised using the 
isoflurane vaporizer system for correction of suture or replacement of surgical clips.   
 
 The experiments were conducted two weeks after the surgery when the 
operated animals gained full recovery. Full recovery from the surgery was 
demonstrated by complete wound healing, returning of the cardiac rhythm to that of 
pre-operative level and resumption of normal behaviour. 
 
2.7.4 Recording of electrocardiography signals and measurement 
electrophysiologic parameters  
 
 Electrocardiographical measurements as well as the body temperatures were 
recorded using the recording program BioSys® software that was supplemented with 
the TSE telemetry system. As shown in Fig. 2.3, recording was carried out by 
bringing the animal with the implanted transmitter device to the vicinity of the 
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specific receiver. The distance between the animal and the receiver was within a 
metre. This was to ensure optimum transmission of the telemetry signals between the 
transmitter and the receiver. 
 
 
Fig. 2.3 Recording of ECG signals with TSE telemetry system  
 
 The basal ECG measurements and body temperatures were recorded for each 
rat on the day of exposure for about 30 minutes prior to injection. Following injection 
of VX, the recording session continued for up to two hours. 
 
 Analysis of the ECG signal recordings was performed by using BioSys® 
analysis software program and the ECG traces were carefully examined on the screen 
of the computer. The following ECG parameters were measured:  
1) RR interval, represented as the interval between the apexes of adjacent R waves;  
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2) QT interval, the distance from the beginning of the QRS complex to the end of T 
wave;  
3) PR interval, measured from the beginning of the P wave to the onset of the QRS 
complex; 
4) Corrected QT or QTc interval was the QT interval corrected for the heart rate by 
means of Bazett's equation: corrected QTc = QT (in seconds) / RR (in seconds)1/2 
(Bazett, 1920).  
  
 In contrast to ECG traces of humans, the T wave was not well defined in small 
rodents (Fraser et al., 1967). Consequently, in this study, the T wave or ventricular 
repolarization was considered to be completed when the ECG signal returned to the 
isoelectric line and before onset of the P wave. Accordingly, to measure the QT 
interval, the end of T wave was measured to be before atrial depolarization i.e. P 
wave which can be determined with high accuracy in the ECG traces recorded in this 
study (Fig. 2.4). The ECG parameters described above were calculated by averaging 
3 ECGs per animal at the particular time point and the means from all the animals 
were then averaged.  
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Fig. 2.4 Measurement of QT interval 
 
 The QT interval was measured from the onset of Q wave to the termination of 
T wave when the signal returned to the isoelectric line. The two cursor lines were 
placed at the beginning of the QRS complex and at the end of the T wave (before the 
onset of P wave) to derive at the duration of the QT interval. 
 
2.7.5 ECG recording schedule for toxicity tests 
  
 ECG measurement was performed in two groups of animals – the group that 
received acute 1LD50 VX and the group that was exposed to chronic dose of 0.4 LD50 
VX. In the group of animals that received the single acute dose of 1LD50 VX, ECG 
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recordings were conducted on the day of intoxication and daily subsequently for up to 
14 days post exposure.  
 
 In the batch of rats that were subjected to repeated low dose injections of 0.4 
LD50 VX daily, recordings were carried out every day for 8 days of injections. After 
the last day of exposure i.e. day 8, measurements were also made every day for 5 
days subsequently.  
 
2.8 HISTOPATHOLOGICAL STUDIES 
 
2.8.1 Perfusion and Fixation 
2.8.1.1 Preparation of fixative  
 
The fixative 10% formalin solution was freshly prepared by diluting 37% 
formaldehyde in deionised water prior to usage. The fixative was used for both 
perfusion of animals and fixation of tissues. 
 
Saline solution or 0.9% sodium chloride solution was prepared by dissolving 






2.8.1.2 Perfusion system 
 
 The system for perfusion of the animals consisted of two reservoirs with one 
containing saline solution and the other holding 10% formalin fixative. Both 
reservoirs had long polyethene tubes extending from the bottom of the containers that 
joined midway to a common line that was connected to a 23 gauge winged needle. 
The needle served as a cannula during perfusion. There were tube clamps on each of 
the tubes that extend from the two reservoirs to release and regulate the flow of saline 
and fixative solutions. An air trap interposed at the bottom of each reservoir functions 
to prevent air bubbles in the perfusion system and enable the speed of perfusion to be 
monitored by counting the number of drops per second.  
 
 Prior to perfusion, the system was prepared by releasing the tube clamp of the 
saline solution reservoir and running the saline solution through the common tube and 
cannula. This ensured that the perfusion line was cleared of any remaining fixative 
solution from the previous perfusion. Any air bubbles in the line were removed in this 
step as well.  
 
2.8.1.3 Perfusion pressure  
 
 Perfusions were carried out under the influence of gravity with the reservoirs 
situated at a height of about 80 cm above the animal. Sufficient perfusion pressure 
was indicated by a moderate flow rate which can be monitored by counting the 
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number of drops of solution dripping in the air trap per second. Excess perfusion 
pressure was demonstrated by solution emerging out of the nose of the animal. 
Reduction of the pressure could be done by turning down the tube clamp slightly. A 
slow flow rate indicated either insufficient pressure or inaccurate insertion of the 
cannula into the heart of the animal. In the former case, the flow rate was adjusted by 
turning up the tube clamp to allow full flow of the solution. The position of the needle 
was readjusted to make certain correct delivery of the solution into the left ventricle 
of the heart in the latter scenario.  
 
2.8.1.4 Anaesthesia of animals 
 
All animals were anaesthetised by injecting fentanyl-fluanisone-midazolam 
mixture solution (3.3 ml per kg of body weight) into the peritoneal cavity. The 
anaesthetic was prepared right before injection by mixing 1 part of hypnorm and 1 
part of midazolam (5 mg/ml) in 2 parts of water. Hypnorm was constituted of 
fentanyl citrate (0.315 mg/ml) and fluanisone (10 mg/ml).  
 
Upon insertion of the needle of the syringe into the lower abdomen of the 
animal, the plunger of the syringe was withdrawn to ensure correct positioning of the 
needle and hence, accurate delivery of the anaesthetic. This was done to make certain 
that the needle had not punctured any blood vessels, the gut or urinary bladder. The 
animals were fully anaesthetised prior to perfusion. The depth of anaesthesia was 
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assessed by pinching one of the toes of the forelimbs with a pair of toothed forceps. A 




 A longitudinal mid-line incision extending from above the sternum to the 
lower abdomen was made with the scalpel. The incision was enlarged by cutting the 
skin and abdominal muscles along the subcostal line that transect the inferior most 
border of the thoracic cage. Lateral cuts on both sides of the diaphragm were made to 
open the thoracic cavity and to let the organs within the thoracic cavity to fall 
backwards. Care was taken not to damage the organs. A sharp pair of scissors was 
used to cut the ribs and intercostals muscles to expose the heart before using a 
haemostat to lift up and clamp the end of the sternum in place.  
 
 Perfusion was started by the insertion of the 23 gauge winged needle near the 
apex of the heart into the left ventricle and then releasing the tube clamp of the saline 
solution reservoir. A nick in the right atrium was made instantly to allow flow of 
saline solution into the blood circulation system of the animal and escape of the return 
circulation through the nick. A total of 150–200 ml of saline solution was allowed to 
flow at high speed. Removal of all blood in the circulation system was indicated by 
the whitish colour of the lungs as well as fluid issuing from the right atrium that was 
cleared of blood. A total of 200 ml fixative solution was run for the subsequent part 
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of the perfusion fixation. At the end of perfusion, the heart, liver, lungs, kidneys, 
biceps femoris and gastrocnemius muscles were dissected out for tissue processing. 
 
2.8.2 Processing of tissue specimens for light microscopy 
 
2.8.2.1 Fixation and dehydration 
 
 The heart and kidney samples were cut transversely in halves and other tissue 
specimens were also cut and trimmed into smaller pieces. They were stored in 
fixative (10% formalin) for 24 hours to allow further fixation. After 24 hours of 
fixation, the tissues were dehydrated in a graded series of ethanol: 30 minutes each in 
70% and 90% alcohol; 1 hour in absolute or 100% alcohol and 2 hours each in 
another two more changes of absolute alcohol. The tissues were then impregnated 
with three changes of toluene for 30 minutes each. All tissue fixation and dehydration 
were conducted at room temperature.  
 
2.8.2.2 Paraffin embedding 
 
 After impregnation in toluene, the specimens were immersed in melted 
paraffin for 2 hours and 30 minutes at 60 °C. They were next transferred to a second 
pot of melted paraffin for another 3 hours. Finally, each specimen was cast in molten 
paraffin in a mould to form a paraffin block. The moulds were placed on the cooling 
platform of the tissue embedder for the paraffin blocks to form and solidify.  
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2.8.2.3 Microtome sectioning 
 
 After the tissue-embedded paraffin blocks were trimmed to remove excess 
paraffin wax, the blocks were cut by sharp steel blades into sections of 6µm thickness 
using a microtome (Leica RM2125). The sections were then laid out and spread on a 
warm water bath (40-45 °C) before being mounted on albumin-glycerin coated slides. 
The slides were placed on a hot plate at 38-42 °C overnight for strong and secure 
adherence to the surface of the slides. All slides were collected in racks and left in the 
incubator (40 °C) until staining. 
 
2.8.2.4 Haematoxylin and Eosin (H & E) staining 
 
 Dewaxing of the sections was carried out by rinsing the slides through two 
changes of xylene, one change of equal parts of xylene and absolute alcohol, two 
changes of absolute alcohol, 90%, 70% and 50% alcohol. The sections were finally 
rinsed with two changes of deionised water. The slides were left in each solution for 
approximately 15 seconds or longer with agitation. Staining of the slides in Harris’s 
haematoxylin stain took 10 minutes. The haematoxylin stain was filtered with 
Whatman® filter paper No. 1 every time before use. Following washing of the slides 
in two changes of deionised water, the sections were left in differentiating fluid (70% 
alcohol with a few drops of hydrochloric acid) for about 10 seconds before rinsing 
once in deionised water. After 3-4 changes of tap water, bluing of the sections were 
done by leaving the slides for 10 minutes in tap water. The sections were finally 
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washed in deionised water before transferring to 3% eosin dye for staining for 15 
minutes. Dehydration of the sections was completed by running the slides quickly 
through 90% alcohol followed by four changes of absolute alcohol, for about 5 
seconds in each solution. The slides were subsequently washed in three changes of 
histoclear before cover slipping. Mountant (Permount) were dripped into the sections 
before placing suitably sized cover slips over the sections. The slides were then left to 
air-dry at room temperature overnight. 
 
2.8.2.5 Observation with light microscope and histologic scoring 
 
 Sections were viewed under the light microscope (Leica). Severity of 
histopathological damages and changes in the organs was scored according to a 
grading system of 0-4. The grading system describes severity of lesions based on the 
approximate percentages of damaged tissue involvement: Grade 0 – nil (0%); grade 1 
– minimal (1-10%); grade 2 – mild (11-25%); grade 3 – moderate (26-45%) and 
grade 4 – severe (>45%) (Singer et al., 1987; McDonough et al., 1995).  The 
following variables were accessed histologically as characterisation of lesions or 
tissue injury: 1) cellular infiltration with polymorphonuclear leukocytes; 2) cellular 






2.9 STATISTICAL ANALYSIS 
 
 All data were expressed as means ± SEM. Statistical computation was 
performed by use of GraphPad Prism. Statistical analyses were carried out using 
Student’s t test to evaluate the effects of nerve agent VX on weight, 
acetylcholinesterase activity, heart rate, body temperature and electrophysiological 
variables. Statistical significance was set at a cut off of 5% or P < 0.05. The levels of 
statistical significance were rated according to the following:  
* P < 0.05 – A probability level of 0.05 or less was considered statistically 
significant;  
** P < 0.005 – Probability level of 0.005 or less was regarded as very significant 
statistically; and 






























CHAPTER THREE OBSERVATIONS AND RESULTS 
 
3.1 ACUTE 1.6 LD50 VX INJECTION WITH DRUG TREATMENT  
3.1.1 Clinical observations after injection 
 
 Five rats were each injected with a single dose of 1.6 LD50 VX (s.c.) in 
addition to three treatment drugs (i.m) namely pyridostigmine bromide (0.13 mg/kg), 
atropine methyl nitrate (2 mg/kg) and pralidoxime chloride (25 mg/kg). The first sign 
of intoxication – mastication or chewing movements around the lips, appeared within 
5 minutes after injection of VX.  Fine facial twitches and facial tremors subsequently 
developed. Thereafter, the animals showed drooping of the head and hind limb 
weakness. The animals became prostrate, lying flat on the ventral side. This 
eventually progressed to rigidity in the upper body with rhythmic swaying of the head 
either from side to side or up and down. Whole body tremors set in followed by 
facial, forepaw and head clonus. The clonic activity was marked by alternating 
muscular contractions and relaxation, occurring in rapid succession. The progression 
to tonic-clonic convulsions ultimately appeared in the animals about 20 minutes after 
VX injection and there were sustained contractures of skeletal muscles. The animals 
demonstrated severe convulsions with lifting of the forelimbs off ground 
occasionally.  
 
 Approximately 40 minutes post injection, the convulsions were accompanied 
by arched backs in the animals in between the episodes of convulsions. All of the 
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animals exhibited straub tails i.e. tails raised straight up vertically in the air. Four of 
the 5 rats lost their righting reflex momentarily and lay on the sides amid attacks of 
convulsions. Salivation occurred in 3 rats while 4 had protrusion of the eyeballs. The 
series of convulsions continued for up to 2 hours with the duration between 
successive convulsion attacks increasing over time. At 24 hours post exposure, 4 
animals survived. The high survival rate despite the high dose of 1.6 LD50 VX was 
attributed to the drug treatment administered to the animals. Loss of righting reflex 
was sustained in the fifth rat with loss of muscle tone. The animal exhibited cyanosis 
or purplish colour in its ears and feet and died over night. The clinical observations 
made was summarised in Table 3.1. 
 
Table 3.1 Clinical observations after s.c. injection of 1.6 LD50 VX 
 Observations No. of rats 
Mastication (chewing movements) 5 
Facial tremors 5 
Hind limb weakness and prostration 5 
Whole body tremors 5 
Facial, forepaw and head clonus 5 
Tonic-clonic convulsions 5 
Straub-tail 5 
Diarrhoea 0 
Loss of righting reflex 4 
Salivation  3 




In addition to the three treatment drugs, the treatment controls received saline 
injections instead of VX. They appeared to have no observable deficit. One rat, 
however, showed masticating movements 30 minutes after injection of treatment 
drugs and saline solution. The intermittent mastication continued for about 40 
minutes. Chewing motion was a non-specific sign and symptom in rats upon exposure 
to exogenous drugs (Casey, 2000; Gao et al, 1998) and it was most likely to be a 
result of the drug treatment action.  
 
3.1.2 Weight profile 
 
 The animals were routinely weighed prior to injection. The average weight of 
the rats challenged with VX was 231.25 ± 8.86 g on the day of injection. The mean 
weight decreased by 6.27% or a reduction of 14.5 g to 216.75 ± 6.02 g after 24 hours. 
In contrast, the average weight of the treatment controls at 232.33 ± 9.33 g was 
measured to be 227 ± 10.02 g 24 hours post-injection. This was a decrease of 2.28% 
of the initial mean weight or a loss of 5.3 g. Although statistical analysis revealed the 
decrease in weight in both groups as statistically insignificant, the P value of the 1.6 
LD50 VX group had a smaller value (P = 0.225) compared to the P value of the 
treatment control group (P = 0.718). The data is shown in Fig. 3.1. The slight 
decrease in the weight of treatment control group was most probably attributed to the 































Fig. 3.1 Average weights of the 1.6 LD50 VX-exposed rats and treatment controls 
 The mean weight of the rats is plotted against days. Dosing day refers to the 
day on which the VX-challenged rats were injected with an acute dose of 1.6 LD50 
VX while the treatment controls received saline injections. Day 1 denotes 24 hours or 
1 day post injection. 1.6 LD50 VX exposed-rats (♦, n = 4) showed a marked decrease 
of 6.27% reduction in the mean weight while the control group (■, n = 3) had a 











3.1.3 Acetylcholinesterase activity 
 
 Blood acetylcholinesterase activity of the rats administered with 1.6 LD50 VX 
decreased significantly from a baseline value of 4.013 ± 0.114 U/gHb by 27.0% to 
2.931 ± 0.181 U/gHb after 24 hours post injection (P < 0.005). In contrast, enzyme 
activity in control rats that were injected with only the drug treatment were not 


























Fig. 3.2 Blood acetylcholinesterase activity in 1.6 LD50 VX-exposed rats and 
treatment controls 
 AChE activity of the 1.6 LD50 VX-exposed rats (n = 4) were significantly 
reduced to 73.0% of its initial values following 24 hours after injection while control 
rats (n = 3) injected with saline and drug treatment were unaffected.  Values are 




         ** 
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3.1.4 Histopathological changes  
 
 Various organs of the four rats that survived exposure to 1.6 LD50 VX 24 
hours after injection were processed for light microscopic examination. Table 3.2 
summarises the degree of histopathological changes observed in the organs.  
 
Table 3.2 Incidence and severity of damages induced by 1.6 LD50 VX in five 
organs 
 
 Heart Kidney Skeletal 
Muscle 
Lungs Liver 
1.6LD50 rat 1 (C) 4 0 0 0 0 
1.6LD50 rat 2 (C) 4 1 0 0 0 
1.6LD50 rat 3 (C) 3 0 1 0 1 
1.6LD50 rat 4 (C) 4 0 0 0 0 
(C) – tonic-clonic convulsions present;  
grade 0 – nil (0%); grade 1 – minimal (1-10%); grade 2 – mild (11-25%); grade 3 – 
moderate (26-45%) and grade 4 – severe (>45%).  
  
3.1.4.1   Cardiac muscle 
 
Control rats with drug treatment  
 Under light microscope, the cardiac muscle cells of the treatment control 
animals 24 hours after injection with normal saline and treatment drugs showed 
normal cardiac muscle morphology. The structure and organisation of the control 
heart muscles was intact and there was no atypical cellular infiltration within the cells 
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or in the interstitium. In Fig. 3.3A, the transverse sections of the cardiac muscles 
revealed densely packed bundles of cardiac fibres. Most cross-sectioned cardiac 
muscle fibres had rounded or smooth-contoured polygonal profiles while some were 
generally more irregular and elongated. Individual muscle fibres as well as bundles of 
the fibres were surrounded by fine connective tissue which contained capillaries, 
venules and arterioles (Fig. 3.3A and 3.3B). In longitudinal sections of the cardiac 
muscle fibres in Fig 3.3C, the distinctive central location of the nuclei was shown and 
extensive cytoplasm branched to present the appearance of a continuous three 
dimensional network. The muscle fibres were disposed vertically in the micrograph 
and showed cross striations along their lengths. In addition to the regular cross 
striations, there was another group of more pronounced cross-bands, the intercalated 
discs which were essentially cell junctions distinctive of cardiac muscles (Fig. 3.3D). 
Occasional fibroblasts were found amidst the cardiac cells and their nuclei are 
typically elongated and relatively narrow (Fig. 3.3D).  
 
1.6 LD50 VX-challenged rats with drug treatment given 
 Myocardial changes were observed after s.c. injection of VX. Cardiac lesions 
were found in all of the animals that survived the acute dose of VX. The lesions or 
areas of cardiomyopathy were mainly seen in the interventricular septum, papillary 
muscles and in the left ventricular walls (Fig. 3.4A). The prevalence of cardiac 
lesions was higher in the latter two regions. All rats that survived 24 hours after 
injection of 1.6 LD50 VX showed severe myocardial injury and inflammatory 
changes. As shown in Fig. 3.4B, the myocardial injuries dominated in the 
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endocardium of the heart. Fig 3.5 shows morphological changes produced by VX, 24 
hours after injection of 1.6 LD50 of VX. Examination of the cardiac muscles of the 
animals showed multiple foci of severe myolysis typified by disruption of myofibrils 
and heavy infiltration of polymorphonuclear inflammatory cells (Fig. 3.5A). 
Interstitial deposition of cellular infiltrates, fibroblasts and amorphous necrotic debris 
were also observed. There were myofibre degeneration and necrosis of myocytes with 
occasional cytoplasmic vacuolations (Fig 3.5B and Fig. 3.6). The active process of 
lymphocytic inflammation was captured by the demonstration of large congregations 
of phagocytes both within the necrotic cardiac myocytes and in the interstitial regions 





















Fig. 3.3 Light micrograph of rat control cardiac muscle 
 (A) Transverse section (TS) of left ventricular cardiac muscle showing 
bundles of muscle fibres. Capillaries (arrows) can be found in the delicate connective 
tissue which envelopes muscle fibres. H & E stain, X 400. (B) TS of interventricular 
septum. Connective tissue CT contains capillaries and sometimes larger vessels, such 
as the venule V in the centre of the muscle fibre bundle. H & E stain, X 400. 








Fig. 3.3 Light micrograph of rat control cardiac muscle 
 (C) Longitudinal section (LS), displaying cardiac muscle fibres branching out 
to form a continuous network. Centrally located nuclei are seen within the muscle 
cells. H & E stain, X 400. (D) LS of a cardiac muscle bundle, showing more obvious 
cross striations. Intercalated discs in the striated fibres can be faintly seen (arrows). 
Occasional fibroblasts F are aligned between the muscle fibres. The nuclei of the 








Fig. 3.4 Distribution of cardiac lesions in rat injected with 1.6 LD50 VX 
 (A) Light micrograph (LM) showing infiltrated cardiac lesions in the left 
ventricular wall and papillary muscle of one of the 1.6 LD50 VX-exposed rats after 24 
hours post VX injection. H & E stain, X 100. (B) TS of left ventricular wall revealing 
widespread infiltration of mononuclear cells particularly in the endocardial region. H 







Fig. 3.5 Cardiac lesions  
 (A) TS (H & E, X 1000) of rat myocardium, revealing infiltration of 
inflammatory lymphocytes, neutrophils and fibroblasts among the muscle fibres and 
in the interstitium between the muscle bundles. (B) High power magnification of 
cardiac muscle (TS) shows myocytes undergoing necrosis. The arrows point to 
regions of myonecrosis and infiltration. The top left corner of the micrograph (block 







Fig. 3.6 Myocardial injury of cardiac muscles  
 (A) TS of cardiac muscles showing disruption of muscle fibres and phagocytic 
infiltration.  Amorphous necrotic debris accumulated amid the degenerating muscle 
cells. H & E, X 400. (B) Many areas of cardiac muscles (TS) showing active necrosis 
of the muscle fibres. Myocyte cytoplasmic vacuolations could also be observed 
(arrows). H & E, X 400. 
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3.1.4.2  Kidney 
 
Control rats with drug treatment  
 Examination of kidneys of the control rats 24 hours after administration of 
saline solution and treatment drugs revealed typical renal organisation and 
morphology with no cellular damage. A sagittal section could be divided into two 
distinct regions: an outer reddish brown-coloured cortex and an inner lighter-coloured 
medulla. Fig. 3.7A shows transverse section of the kidney of a treatment control 
animal 24 hours after injection with treatment drugs and saline solution. The renal 
cortex consisted of renal corpuscles, along with convoluted and straight tubules of the 
nephron, the collecting tubules and an extensive vascular supply. The functional unit 
of the kidney, the nephron, was made up of the renal corpuscle and the renal tubule. 
Fig. 3.7A reveals the renal corpuscles and medullary rays, which were series of 
vertical striations that emanated from the medulla. In high power magnification (Fig 
3.7B), the renal corpuscle appeared as a spherical structure whose periphery was 
composed of a thin capsule, the Bowman’s capsule, that enclosed a narrow clear 
space (urinary space) and a unique capillary tuft or the glomerulus.  
 
1.6 LD50 VX-challenged rats with drug treatment given 
Normal renal cellular morphology was displayed by 3 of the 4 rats that 
survived the high acute dose of 1.6 LD50 VX. Only one rat had mild congestion of red 
blood cells among the cells 24 hours post injection and the extent of damage was 
minimal. Fig 3.8A reveals small dispersed areas of hyperaemia or accumulation of 
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red blood cells in the kidney of the rat. The congregations of red blood cells were 
small, multifocal and distributed between the tubules and renal corpuscles (Fig. 




























Fig. 3.7 Light micrograph of control rat kidney  
 (A) TS of the renal cortex divided into the cortical labyrinth and the medullary 
rays. The cortical labyrinth contains renal corpuscles RC which are surrounded by the 
proximal and distal convoluted tubules (PCT and DCT). The medullary rays MR, cut 
longitudinally in this micrograph, are presented as elongated profiles between the 
cortical labyrinth regions. H & E, X 200. (B) High magnification of renal corpuscle, 












Fig. 3.8 Hyperaemic kidney in VX-exposed rat  
 (A) TS of kidney of the single 1.6 LD50 VX-exposed rat that had mild 
haemorrhage, showing aggregation of red blood cells in the interstitial region. The 
surrounding areas appear normal. H & E stain, X 100. (B) Higher magnification of 
the area of hyperaemia showing small dispersed assemblages of red blood cells 
between the tubules and renal corpuscles. H & E stain, X 200. 
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3.1.4.3  Skeletal muscle 
 
Control rats with drug treatment  
 Both gastrocnemius and biceps femoris muscle fibres in the control rats 
showed normal skeletal muscle morphology and structure. The muscle fibres were 
arranged in bundles which were enveloped by sheaths of connective tissue, the 
perimysium. Within the muscle fibre bundles, endomysium surrounded each muscle 
fibre. In Fig. 3.9A, the transverse sections showed individual muscle fibres enclosed 
by endomysium. Peripherally located nuclei lay at the borders of the muscle fibres. 
Fig. 3.9B shows numerous densely stained flattened nuclei located at the periphery of 
the fibres at fairly regular intervals. The muscle fibres were presented as elongated, 
unbranched multinucleated striated structures consisting of myofibrils. Longitudinal 
section of muscle fibres displayed cross striations of alternating light and dark bands 
(I bands and A bands) at high magnification in Fig. 3.9C. 
 
1.6 LD50 VX-challenged rats with drug treatment given 
 Musculature typical of the normal skeletal muscle morphology was seen in 3 
of the 4 VX-challenged rats 24 hours after s.c. injection. Only one rat demonstrated 
slight infiltration of mononuclear cells (Fig. 3.10). The mild cellular infiltration was 
focused, appearing only at a single region. The myofibrils within the muscle fibres 
were interrupted and disrupted solely in the point of cellular infiltration. Myonecrosis 








Fig. 3.9 Light micrograph of rat control skeletal muscle  
 (A) TS of gastrocnemius muscle, showing the compact organisation of muscle 
fibres. The fibres are encircled by delicate connective tissue sheaths, endomysium, 
with nuclei positioned at the periphery of the muscle fibres. H & E stain, X 400. (B) 
LS reveals striated muscle fibres containing numerous flattened nuclei beneath the 
sarcolemma. Myofibrils, constituents of the muscle fibres, can be seen too. H & E 










Fig. 3.9 Light micrograph of rat control skeletal muscle  
 (C) High power magnification of LS reveals cross striations in the skeletal 

























Fig. 3.10 Cellular infiltration seen in VX-challenged rat 
 (A) LS of gastrocnemius muscle of rat with infiltration of mononuclear cells. 
The permeation of cellular infiltrates was focal, limited and not extended. Necrosis 
and muscle fibres degeneration were exclusive to this region. Surrounding areas 
shows normal striated musculature. H & E stain, X 200. (B) Higher magnification of 
infiltrated area. H & E stain, X 400. 
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3.1.4.4  Liver 
 
Control rats with drug treatment  
 Observations of the liver sections of rats injected with saline solution and 
treatment drugs showed no abnormalities. The structure of the liver was described in 
terms of functional units – hepatic lobules. As shown in Fig. 3.11, stacks of 
anastomosing plates of hepatocytes were 1-2 cells thick and separated by the 
anastomosing system of sinusoids that perfused the cells with mixed portal and 
arterial blood. The top left area of the light micrograph shows a venule at the centre 
of the lobule called the central vein, into which the sinusoids drained. The plates of 
cells radiated from the central vein to the periphery of the lobule. Portal areas or 
portal canals existed at the angles of the liver lobule. The portal canals were loose 
stromal connective tissue characterised by the presence of portal triads. A portal triad 
consisted of hepatic artery, portal vein and bile duct.  
 
1.6 LD50 VX-challenged rats with drug treatment given 
 Histological examination of the liver sections of rats that survived the 1.6 
LD50 dose of VX revealed no major hepatic damages. Only one of the 4 rats injected 
with VX showed mild lymphocytic infiltration and early necrosis of the hepatocytes 
(Fig.3.12). As in the skeletal muscles and kidneys, the extent of damage of the liver is 











Fig. 3.11 Light micrograph of rat control liver  
 Light micrograph of liver section taken from a control rat 24 hours after 
injection of saline solution and three treatment drugs, showing normal structure and 
organisation. On the top left corner is the central vein CV, into which sinusoids S 
normally drained. Interconnecting sheets of hepatocytes H are disposed in a radial 
pattern from the central vein to the perimeter of the lobule. Also present at the bottom 
left corner of this micrograph is a portal triad, which carries the branches of the 


























Fig. 3.12 An area of cellular infiltration in the liver  
 (A) The micrograph shows mononuclear cellular infiltrates in the liver 24 
hours after injection. The area of infiltration is isolated and confined. H & E stain, X 
200. (B) High power view of hepatic lesion. The small polymorphonuclear infiltration 
disrupts the limiting plate of the hepatocytes locally and is accompanied by mild 
necrosis of the hepatocytes. H & E stain, X 400. 
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3.1.4.5  Lungs  
 
Control rats with drug treatment  
 Sections of lungs from control rats showed normal cellular morphology and 
organisation in the lung parenchyma (Fig. 3.13A). Terminal bronchioles formed 
short, thinner-walled respiratory bronchioles. Each respiratory bronchiole in turn was 
further divided into alveoli ducts which consequently opened along their length into 
numerous alveolar sacs and alveoli. Fig. 3.13B shows the alveolar walls being thin 
and delicate. Surrounding each alveolus was a rich network of pulmonary capillaries 
supplied by pulmonary vessels that followed the entire course of the airways. Each 
alveolus composed of a pocket, open at one side and lined by flattened epithelial 
cells. The epithelium provided a continuous lining to each alveolus and consisted 
cells of two types.  Type I pneumocytes were large, flattened cells that made up most 
of the alveolar surface area. The cytoplasm of these cells covered a substantial area, 
resulting in the characteristic densely stained nuclei being infrequently seen. The 
second epithelial cell type, known as type II pneumocytes, were roundly shaped and 
occupied a smaller proportion (5%) of the surface area of the alveoli.  
 
1.6 LD50 VX-challenged rats with drug treatment given 
 No morphological changes or lesions were observed in the lung sections of all 
of the rats exposed to 1.6 LD50 VX 24 hours after injection. As displayed in Fig. 3.14, 
the structure and organisation of the lungs in the VX-intoxicated rats were similar to 
that of the control rats. The lung tissues were devoid of any anomalous cellular 
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infiltrates and there were no signs of inflammatory processes or oedema. The alveoli 
were thin-walled and well-aerated as in lungs of the controls, facilitating efficient 















































Fig. 3.13 Light micrograph of rat control lungs 
 (A) Light micrograph of control lungs shows normal pulmonary organisation 
and cellular morphology. Shown here are two terminal bronchioles accompanied by a 
pulmonary vessel. H & E, X 200. (B) High power magnification of the lung section 
reveals pulmonary vessels V, respiratory bronchioles, alveolar ducts, alveolar sacs 
and thin-walled alveoli. The arrows points to two of the many alveoli shown in this 







Fig. 3.14 Normal lung morphology in 1.6 LD50 VX-exposed rats 
 (A) LM of lungs from 1.6 LD50 VX-exposed rats shows normal cellular 
morphology. H & E, X 200. (B) Amplification of the lung section showing normal 
pulmonary morphology. Shown here are the Type I pneumocytes P1, type II 
pneumocytes P2 and pulmonary vessels V. P2 have large rounded nuclei with 
prominent nucleoli compared the more abundant P1 which are generally large 
flattened cells. The alveolar walls are enveloped by rich networks of pulmonary 








3.2 ACUTE 1 LD50 VX INJECTION  
 
3.2.1 Clinical observations after injection 
 
 A total of 40 rats were injected with 1 LD50 VX (s.c.) without any drug 
treatment and 22 rats survived. The list of clinical signs and symptoms of poisoning 
recorded in the rats injected with the single dose of 1 LD50 VX were rather similar to 
that of the rats injected with an acute dose of 1.6 LD50 VX. Table 3.3 summarises the 
clinical signs exhibited by the survivors.  
 
 The duration taken for the appearance of the signs of nerve agent poisoning 
was longer than that observed with the rats exposed to 1.6 LD50 VX. For example, the 
first sign of intoxication – chewing movements (mastication) appeared around 12 
minutes after injection as opposed to 5 minutes post-injection in the 1.6 LD50 VX 
group of rats. All animals demonstrated mastication, tremors in the facial muscles, 
and weakness in the hind legs and were prostrate.  Tremors involving the whole body 
musculature as well as clonic movements of the head, face and forepaw occurred in 
the 22 rats. However, 18 out of the 22 rats or 81.82% of the rats had tonic-clonic 
convulsions in which the muscular spasms were continuous and persistent. 
Emergence of convulsions began approximately 35 minutes post-injection and the 
convulsions were persistent up to the 2 hours. 14 rats (63.64%) demonstrated straub 
tails while 6 (27.27%) had momentary loss of right reflex. 3 rats (13.64%) had 
diarrhoea, a symptom which was absent in the1.6 LD50 VX group. Salivation and 
protruding eyes were seen in 11 (50%) and 19 rats (86.36%) respectively. Only one 
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rat (4.55%) was presented with lacrimation.  
 
Table 3.3 Clinical observations after s.c. injection of 1 LD50 VX 
 
 Observations No. of rats 
Mastication (chewing movements) 22 
Facial tremors 22 
Hind limb weakness and prostration 22 
Whole body tremors 22 
Facial, forepaw and head clonus 22 
Tonic-clonic convulsions 18 
Straub-tail 14 
Diarrhoea 3 





 At 24 hours or one day post injection, the animals appeared weak and had an 
abnormal hunched posture. Most animals demonstrated mastication as well as facial 
tremors too. In addition, prophyrin staining around the eyes which was indicative of 
the animals under distress was observed too. Lameness, reluctance to move and 
anorexia were common signs among the rats. The fur of most animals was unkempt 
and respiration was slow and shallow. These signs continued on day 2 post exposure. 
However, by the fifth day, the signs of distress were greatly lessen and all of the 
survivors were able to move and feed normally. Exhibition of normal behaviour in the 
intoxicated rats was subsequently seen up to the fourteenth day.  
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 There were no clinical signs and symptoms of poisoning observed in the 
control animals that were injected with saline solution. The animals displayed normal 
behaviour.  
 
3.2.2 Weight profile 
 
 The mean weight of the 22 rats that survived the 1 LD50 VX challenge was 
211.41 ± 3.60 g before they were administered with the nerve agent. At 24 hours after 
injection, the average weight decreased by 20.05 g (or by 9.48%) to 191.36 ± 4.07 g 
(P < 0.001). Weight of the survivors remained low on day 2 post intoxication at an 
average of 190.44 ± 5.85 g (P < 0.001). The initial mean weight was regained by the 
fifth day post exposure and thereafter, the VX-intoxicated rats showed normal body 
weight gain as in the control rats up to day 14 post exposure. The control group which 
were injected with saline solution on the day of dosing did not exhibit loss in weight 
throughout the 14 days. The statistics on the body weights of both groups of rats is 





























































Fig. 3.15 Mean weights of the 1 LD50 VX-exposed rats and control rats up to 14 
days post injection 
 Rats exposed to 1 LD50 VX received the acute dose without treatment on the 
dosing day while the controls were given saline injections. As shown in the figure, the 
weights of the VX-exposed rats (♦, n = 22) dropped drastically after 24 hours on day 
1 post injection. The VX-challenged group demonstrated a steady increase in body 
weight after day 5 post intoxication till day 14. The control rats (■, n = 4) displayed 
normal body weight gain all through the 14 days. Values are presented as means ± 










    *** 
  *** 
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3.2.3 Acetylcholinesterase activity 
 
 Analysis of blood drawn at 1 hour after administration of 1 LD50 VX showed 
significant reduction in AChE activity. The enzyme activity in the VX-challenged rats 
decreased to 63.6% of its initial value (P < 0.001) while enzyme activity in the 
control rats that received saline injections remained approximately the same. As 
presented in Fig. 3.16, although AChE activity in the VX-challenged rats was 
regained considerably by day 7 post injection, the activity was still suppressed at 


























Fig. 3.16 Blood acetylcholinesterase activity of the 1 LD50 VX-exposed rats and 
control rats 
 Assay of whole blood from VX-challenged rats (♦, n = 6) taken an hour after 
injection with 1 LD50 VX revealed drastic decrease in AChE activity from an original 
average baseline value of 4.283 ± 0.086 U/gHb to 2.726 ± 0.018 U/gHb. After 7 days 
following exposure, AChE activity remained suppressed at 3.677 ± 0.083 U/gHb. 
Enzyme activities of control rats (■, n = 6) were not significantly changed 
statistically. Values are presented as means ± SEM; *** P < 0.001. 
     *** 
    *** 
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3.2.4 Time study profile of histopathological changes  
 
 The rats that survived the acute exposure to 1 LD50 VX were perfused on 
different days post injection. The days selected for histological examination were 1 
day, 2 days, 5 days, 9 days and 14 days post injection. Results of the histologic 
scoring of the five organs are presented in Table 3.4.  
 
 Tonic-clonic convulsion was used as one of the benchmarks for severe 
intoxication in this study as it had been established as one of the standard clinical 
signs and symptoms associated with severe nerve agent poisoning. Eighteen rats that 
















Table 3.4 Incidence and severity of damages induced by 1 LD50 VX in the five 
organs on various days post exposure 
 
Heart Kidney Skeletal 
Muscle 
Lungs Liver 
1 day post injection      
1 LD50 day 1 rat 1 (C) 1 2 0 0 0 
1 LD50 day 1 rat 2 (C) 0 1 1 0 0 
1 LD50 day 1 rat 3 2 1 0 0 0 
1 LD50 day 1 rat 4 (C) 2 1 2 0 0 
2 days post injection      
1 LD50 day 2 rat 1 (C) 2 1 0 0 0 
1 LD50 day 2 rat 2 (C) 2 1 1 0 0 
1 LD50 day 2 rat 3 (C) 0 1 2 0 0 
1 LD50 day 2 rat 4 (C) 1 1 1 0 0 
5 days post injection      
1 LD50 day 5 rat 1 (C) 1 0 0 0 0 
1 LD50 day 5 rat 2 (C) 0 1 0 0 0 
1 LD50 day 5 rat 3 (C) 1 0 1 1 0 
1 LD50 day 5 rat 4 2 0 0 0 0 
9 days post injection      
1 LD50 day 9 rat 1 (C) 1 0 0 0 0 
1 LD50 day 9 rat 2 (C) 2 0 0 0 0 
1 LD50 day 9 rat 3 0 1 0 0 0 
1 LD50 day 9 rat 4 (C) 0 0 0 0 0 
14 days post injection      
1 LD50 day 14 rat 1 (C) 0 0 0 0 0 
1 LD50 day 14 rat 2 (C) 0 0 0 0 0 
1 LD50 day 14 rat 3 0 0 0 0 0 
1 LD50 day 14 rat 4 (C) 0 0 0 0 0 
1 LD50 day 14 rat 5 (C) 2 1 0 0 0 
1 LD50 day 14 rat 6 (C) 0 0 0 0 0 
(C) – with tonic-clonic convulsions; grade 0 – nil (0%); grade 1 – minimal (1-10%); 
grade 2 – mild (11-25%); grade 3 – moderate (26-45%) and grade 4 – severe (>45%)  
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 All of the control animals showed no histopathological changes in the organs 
examined. Similar to the treatment controls which received the treatment drugs and 
saline solution, normal tissue organisation and cellular morphology in the five organs 
was observed.  
 
3.2.4.1   Cardiac muscle  
 
 Most animals that were sacrificed 24 hours post injection of 1 LD50 VX 
presented minimal to mild cardiac damage. Only one did not show any cardiac 
damage. The cardiac lesions were scattered, multifocal and concentrated in the 
interventricular septum, left ventricular and papillary muscles (Fig. 3.17A). In 
addition, marked inflammatory changes were seen in the endocardial region. Fig. 
3.17B shows the typical type of cardiac damage observed in the rats perfused 24 
hours after injection of 1 LD50 VX. Lesions were mostly confined to small areas. 
Acute cardiac myofibre necrosis and infiltration of mononuclear cells, lymphocytes 
and fibroblasts (Fig. 3.18A) was frequently observed. At the dose of 1 LD50 VX, 
minimal to mild heart lesions were characterised by disruption and degeneration of 
individual myofibre (Fig. 3.18B). Cardiac cells undergoing necrosis and degeneration 
had a shrunken appearance. The necrotic cells were surrounded by phagocytic 










Fig. 3.17 Cardiac injury in 1 LD50 VX challenged rat 
 (A) Light micrograph of cardiac muscle, showing the papillary muscle and left 
ventricular wall as the most frequently affected areas (arrows). H & E stain, X 100. 
(B) High power magnification of cardiac damage in myocardium. Focal cardiac 
lesions are multiple, scattered and composed mainly of mononuclear cellular 
infiltrates, fibroblasts and occasionally lymphocytes. Degeneration and disruption of 






Fig. 3.18 Cardiac muscle damage after injection of 1 LD50 VX 
 (A) TS of left ventricular muscular wall of a rat examined on day 5 post 
injection revealing an area infiltrated by polymorphonuclear leukocytes and 
fibroblasts (arrows). The cardiac lesions are characteristically focused and exclusive. 
H & E stain, X 200. (B) Individual necrotic cardiac myofibres in the centre section of 
the micrograph (arrow) undergoing degeneration 24 hours post injection. The 
disintegrating myofibres appears shrunken and interstitial deposition of necrotic 
debris can be seen among the muscle bundles. H & E stain, X 400. 
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 The degree and incidence of histopathological damage in the cardiac muscles 
of rats perfused 2 and 5 days after 1 LD50 VX injection were fairly similar to that 
observed in the cardiac muscles of rats perfused after 24 hours. The lesions were 
similarly located in the interventricular septum, left ventricular wall and papillary 
muscles. Likewise, the type of inflammatory changes induced in the myocardium was 
identical. As in the group of rats examined 24 hours post injection, only 1 in 4 of the 
rats each in the day 2 and day 5 groups presented no evidence of histopathological 
lesions in the heart. The average histological scores in the day 1 and day 2 group were 
both 1.25 and the score in the day 5 group was 1.  
 
  Beginning of repair of the necrotic lesions was detected on the 9th day after 
injection. Additionally, the incidence of cardiac lesions was reduced and was seen in 
only 2 out of 4 rats. In rats that were presented with cardiac injury, the extent of 
cardiac damage was less severe. Areas of acute myolysis were more limited in size 
and less numerous affected regions were observed (Fig. 3.19A). Less frequently 
detected also were the infiltration of mononuclear cellular inflammatory cells. 
Amorphous necrotic debris among the degenerated cardiac cells was rarely observed. 
Cardiomyopathy appeared to be almost totally resolved by day 14 following 
exposure. 5 out of 6 animals examined on day 14 post exposure showed no 
histological evidence of cardiac muscle damage. In the one rat that had cardiac 
damage, the level of injury was mild and affected areas showed regeneration of 









Fig. 3.19 Resolution of cardiac damage on Day 9 and 14 post 1 LD50 VX exposure 
 (A) TS of heart section of rat 9 days after injection of 1 LD50 VX. The cardiac 
lesions are notably smaller in size and less distributed compared to that observed in 
day 1, 2, and 5. H & E stain, X 200. (B) Light micrograph of a resolving cardiac 
lesion in the left ventricular wall on day 14 post exposure. Infiltrated regions are 
undergoing self-reparation (arrows) and regeneration of cardiac cells can be seen. H 
& E stain, X 200. 
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3.2.4.2   Kidney 
 
 Renal histological changes were observed in all VX-exposed animals after 24 
and 48 hours following the 1 LD50 VX challenge but the extent of injury was not 
severe. Permeation of mononuclear inflammatory cells (Fig. 3.20A) was observed in 
one rat perfused 24 hours after injection. The infiltration was restricted to a region in 
the renal cortex. Another rat developed fibrosis in the outer cortex 24 hours post VX 
challenge. As can be seen in Fig. 3.20B, the stretch of fibrotic mass disrupted the 
cellular organisation of the cortex. The fibrotic area was relatively large as it was 
observed in most of the kidney sections. In the other 2 rats examined 24 hours after 
injection, hyperaemia or accumulation of red blood cells was noted in the interstitium 
of renal cortex and medulla. 
  
 All of the rats sacrificed 48 hours following VX injection had hyperaemic 
kidneys too. The hyperaemia was extensive and consisted of assemblages of red 
blood cells spanning from the cortex to the outer medulla. As shown in Fig. 3.21, the 
aggregates of red blood cells resided between the tubules, renal corpuscles and 














Fig. 3.20 Histological changes in 1 LD50 VX exposed rats 24 hours post exposure 
 (A) TS of 1 LD50 day 1 rat 4 revealed an area of cellular infiltrates in the renal 
cortex. Plasma cells, fibroblasts as well as other mononuclear cells constitute the 
infiltrates. H & E stain, X 200. (B) TS of 1 LD50 day 1 rat 2 showing a continuous 
stretch of fibroid mass in the outer renal cortex. The mass of fibrotic body disrupts the 
immediate morphology of the cortex and the localised region is devoid of renal cells. 








Fig. 3.21 Hyperaemia in kidney 24 hours post 1 LD50 VX exposure 
 (A) TS of a hyperaemic kidney in a VX-challenged rat revealing assemblies of 
red blood cells in the cortex. H & E stain, X 200. (B) High power magnification of a 
region of the renal infarct. Congregations of red blood cells accumulated between the 
medullary rays and tubules. H & E stain, X 400. 
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 There was evident resolution of renal damage beyond day 5 post exposure. 
Only 1 rat each in the day 5 and day 9 groups showed hyperaemia in the kidneys. The 
affected areas were remarkably less widespread and assemblages of red blood cells in 
the cortex and medulla were relatively smaller in size. Moreover, no signs of 
inflammatory cellular body infiltration or fibrosis were detected in the two rats. In the 
group of rats perfused on day 14, only 1 out of 6 rats had hyperaemic kidneys and the 
degree of engorgement of red blood cells in the infarct regions was mild. The other 5 
rats showed normal renal morphology. 
 
3.2.4.3  Skeletal muscle  
 
 Inflammatory changes appeared in 2 animals 24 hours post injection and in 3 
animals 48 hours post injection. In all cases, the degree of damage was mild. The 
muscle lesions existed as numerous miniature areas of myonecrosis. As shown in Fig. 
3.22A which was taken from one of the rats 24 hours post exposure, there were two 
areas of muscle fibres undergoing acute inflammation, leaving the targeted regions 
devoid of myofibrils. The confined regions of muscle damage contrasted strongly 
amongst the unaltered normal muscle cells. Fig. 3.22B reveals the affected areas as 
sites being infiltrated with mononuclear cellular bodies and degeneration of the local 
myofibrils could be seen. Regions infiltrated with inflammatory cells were clear of 
muscle fibres. Cross striations were absent in the necrotic fibres as well. Furthermore, 
slight disruption in the orientation of myofibrils in the vicinity of the targeted area 






Fig. 3.22 Muscle infiltration 24 hours after injection with 1 LD50 VX 
 (A) Penetration of cellular infiltrates in the muscle fibres (LS) is shown. 
Adjacent muscle fibres were unaffected and displayed normal cellular morphology. 
H&E stain, X 200. (B) High power view of muscle lesion revealing infiltration of 
inflammatory mononuclear cellular aggregates. An area of myofibrils is in the 
dynamic process of degeneration and necrosis (arrow). Phagocytes can be observed 
immediately above the infiltrated region. H&E stain, X 400. 
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As in the kidneys, tissue repair took place thereafter and no muscle lesions 
were observed beyond day 5 post exposure. Only one rat demonstrated muscle lesions 
on day 5 following injection. The muscle damage was significantly reduced in 
intensity and extent of myonecrosis and cellular infiltration. Disruption of myofibrils 
was not observed. Rats examined on day 9 and day 14 displayed normal skeletal 
muscle histology. 
 
3.2.4.4  Lungs 
 
 With the exception of one rat, neither histological damage nor inflammatory 
changes in the lungs was detected in the intoxicated animals up to 14 days after 
injection with 1 LD50 of VX. The only rat that presented histopathological changes in 
the lungs was in the day 5 group. Minimal pulmonary inflammatory changes was 
observed and consisted of interstitial lymphocytic infiltrates (Fig 3.23A). Mild 
pulmonary congestion within capillaries in the alveolar wall was detected. Fig. 3.23B 
shows a congested region packed with numerous mononuclear cellular bodies and red 















Fig. 3.23 Pulmonary changes in rat lungs 
 (A) Light micrograph of a rat lungs showing infiltration of inflammatory 
leukocytes in the alveolar tissue. Plasma cells were detected in the infiltrate mass as 
well. H & E stain, X 400. (B) TS of lungs of the same rat revealing pulmonary 
congestion with plasma cells (arrows) and other mononuclear cells. The alveolar 
walls are filled with red blood cells. H & E stain, X 400. 
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3.2.4.5   Liver 
 
 All 22 rats that received injection of 1 LD50 VX showed normal hepatic 
morphology as in the control rats. No changes were detected on the different days 
post exposure.  
 
3.2.5 Correlation between cardiac damage and convulsions 
  
 In view of the histopathological finding that resolution of myocardial injury 
had commenced on day 9 following 1 LD50 VX exposure, only rats examined on day 
1, 2 and 5 post exposure were assessed for the relationship between cardiac damage 
and tonic-clonic convulsions. Among the 12 rats dissected on day 1, 2 and 5 after VX 
administration, convulsive activity was observed in 10 rats and absent in 2 rats. 3 of 
the 10 rats which experienced convulsions were detected with mild myocardial 
changes of grade 2 while 4 of the 10 rats were presented with minimal myocardial 
changes (grade 1). The remaining 3 rats which underwent convulsions had no 
histological changes in the cardiac muscles. Additionally, myocardial injury was not 
exclusive in the rats which had convulsive activity as the 2 rats which had no 
convulsions developed mild cardiac injury (grade 2). 
 
 Therefore, analysis of the association between extent of myocardial damages 
and presence of tonic-clonic convulsions revealed poor correlation connecting 




3.2.6.1  Day of exposure 
3.2.6.1.1   Physiologic and electrocardiographic data 
  
 ECG recordings were conducted in 6 rats challenged with 1 LD50 VX. 2 rats 
died from nerve agent poisoning after 53 and 80 minutes respectively. Basal 
physiologic and electrocardiographic values of the rats were recorded for 30 minutes 
prior to exposure and recording continued for 120 minutes post injection. The 
physiologic parameters measured included heart rate and body temperature while the 
electrocardiographic parameters analysed were QT interval, RR interval, QTc interval 
and PR interval.  The data is shown in Table 3.5.  
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(n = 6) 
 
30 min 
(n = 6) 
 
60 min 
(n = 5) 
 
90 min 
(n = 4) 
 
120 min 
(n = 4) 
 
Heart rate (beats/min) 
 
450 ± 21  
 
295 ± 15*** 
 
302 ± 21*** 
 
256 ± 19*** 
 
255 ± 23*** 
 
Body temperature (°C) 
 
37.7 ± 0.3 
 
35.3 ± 0.4** 
 
33.9 ± 0.7*** 
 
33.9 ± 1.0** 
 
33.9 ± 1.0** 
QT interval (ms) 94 ± 6 166 ± 9*** 185 ± 22** 239 ± 71* 302 ± 107* 
RR interval (ms) 135 ± 6 220 ± 11*** 250 ± 20*** 312 ± 76* 379 ± 119* 
QTc interval (ms) 254 ± 11 353 ± 12*** 371 ± 32** 417 ± 71* 472 ± 96* 
PR interval (ms) 42 ± 1 59 ± 2*** 68 ± 2*** 73 ± 5*** 77 ± 12** 
Values represent means ± SEM. 
* P < 0.05; ** P < 0.005; *** P < 0.001 
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 The average heart rate of the 6 animals was 450 ± 21 beats per minute at 
baseline and decreased drastically by 34.4% 30 minutes post 1 LD50 VX injection (P 
< 0.001). As illustrated in Fig. 3.24, the decline in heart rate continued up to 120 
minutes after injection, reaching a lowest of 255 ± 23 beats per minute (P < 0.001).   
Likewise, the drop in mean body temperature of the animals was the steepest in 
gradient 30 minutes after injection, from 37.7 ± 0.3 °C to 35.3 ± 0.4 °C i.e. by 6.4% 
(P < 0.005) (Fig. 3.25). The decrease in body temperature stabilised at 33.9 ± 0.7 °C, 
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Fig. 3.24 Heart rate of the animals injected with 1 LD50 VX 
 The decrease in heart rate was the most substantial within 30 minutes after 
injection. The decline in heart rate continued thereafter, reaching a minimum of 255 ± 
23 beats per minute. All values are presented as means ± SEM (n = 6 at baseline and 
30 min; n = 5 at 60 min; n = 4 at 90 min and 120 min). * P < 0.05; ** P < 0.005; *** 
P < 0.001 
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Fig. 3.25 Body temperature of animals injected with 1 LD50 VX 
 The average body temperature of the animals decreased to a large extent in the 
first 60 minutes post exposure before reaching a plateau at 33.9 ± 0.7 °C. All values 
are presented as means ± SEM (n = 6 at baseline and 30 min; n = 5 at 60 min; n = 4 at 
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Both QT and QTc intervals were prolonged significantly. The duration of QT 
interval increased by 76.6% relative to the baseline interval after 30 minutes (P < 
0.001) and the QT interval corrected for heart rate i.e. QTc interval was lengthened 
by 39.0% (P < 0.001). As presented in Fig. 3.26, further continual prolongation of 
both QT and QTc intervals was evident even up to 120 minutes after injection. At 
120 minutes, the mean QT interval was increased by more than twofold or 221.3% 
of its initial value to 302 ± 107 ms (P < 0.05). The mean QTc interval of the animals 
was amplified by 85.8% of its baseline value after 120 minutes (P < 0.05).  
 
In addition to the decrease in mean heart rate shown in Fig 3.24, extension of 
RR interval once again verified the bradycardia. The mean RR interval was 
prolonged by 180.7% at the end of 120 minutes (P < 0.05). Likewise, the duration of 
PR interval was significantly delayed throughout the 2 hours of recording. Although 
the overall increase was the least in PR interval, it was nevertheless significantly 
augmented by 83.3% of its initial value recorded prior to exposure (P < 0.001). Fig. 






























Fig. 3.26 Changes in electrocardiographic parameters induced by 1 LD50 VX 
 The electrocardiographic parameters were calculated from the ECG traces recorded 30 minutes before injection of 1 LD50 VX 
and 120 minutes after exposure.  Prolongation of the electrocardiographic parameters QT, RR, QTc and PR intervals were all 
statistically significant and further augmentation of the four parameters persisted up to 2 hours. At the end of the 2 hours of ECG 
recording, the increase in QT interval was the greatest (221.3%), followed by RR interval (180.7%), subsequently QTc interval 
(85.8%) and finally PR interval (83.3%). All values are presented as means ± SEM (n = 6 at baseline and 30 min; n = 5 at 60 min; n = 
4 at 90 min and 120 min). * P < 0.05; ** P < 0.005; *** P < 0.001
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Fig. 3.27 Time profile of electrocardiographic parameters after exposure to 1 
LD50 VX  
 The durations of four electrocardiographic parameters derived from the ECG 
waveforms were expressed against time to demonstrate the time trends in the 
prolongations over 120 minutes. All values are presented as means ± SEM (n = 6 at 
baseline and 30 min; n = 5 at 60 min; n = 4 at 90 min and 120 min). * P < 0.05; ** P 
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3.2.6.1.2 Cardiac rhythm 
 
Sinus bradycardia was detected in all 6 animals injected with 1 LD50 VX as 
the first indication of cardiotoxicity. Sinus bradycardia or slow beating that 
originated in the sinus atrial node was shortly complicated by first-degree 
atrioventricular (AV) block within 10 minutes after injection. As shown in Fig. 3.28, 
first-degree AV block was typified by prolonged PR intervals with regular cardiac 
rhythm. Despite prolongation in the conduction, the rhythm was regular since all 
sinus beats were conducted to the ventricles.  
 
The first-degree AV block progressed to type I second-degree AV block (AV 
Wenckebach or Mobitz Type I block) after a mean time of 21.7 ± 2.7 minutes post 
injection. Fig 3.29 shows typical type I second-degree AV blocks in which impulses 
were progressively delayed at the AV node until a single P wave was not conducted. 
The pauses were characteristically less than twice the shortest cycle. The sequence 
was usually repeated after the pause.  
 
Type II second-degree AV block, also known as Mobitz Type II block, was 
observed in all VX-poisoned animals as well. This form of arrhythmia surfaced soon 
after appearance of type I second-degree AV block. As shown in Fig. 3.30, impulses 
were delayed and blocked intermittently every 3 to 5 impulses. Unlike type I second-
degree AV block, type II AV block had fixed PR interval. Hence, stable PP interval 




The AV block developed into arrhythmias with longer durations between the 
QRS complexes, resulting in more significant QT prolongation. Onset of ventricular 
tachycardia of the ‘torsades de pointes’ (TdP) type manifested around 34.2 ± 8.1 
minutes following injection in 5 of the 6 animals exposed to 1 LD50 VX. TdP was 
not detected in one animal. Emergence of TdP as distinctive undulating and spindle-
patterned series of waveforms is shown in Fig. 3.31. The QRS complexes appeared 
to twist around the isoelectric line in a bizarre manner. Although an episode of TdP 
was observed to last for as long as 4 seconds, each period of TdP typically ranged 
from 1 to 2 seconds. The duration between each TdP event was noticed to be as 
close as 2 seconds. Preceding the appearance of TdP were usually short-long cycles, 
as illustrated in Fig. 3.32A. Besides AV blocks of the first- and second- degree (type 
I and type II) forms, consecutive and regular extreme pauses between impulses were 
commonly observed between the episodes of TdP (Fig. 3.32B).  The intense pauses 














Fig. 3.28 First-degree atrioventricular (AV) block 
 The top ECG strip demonstrates first-degree AV block in a 1 LD50 VX-challenged rat 10 minutes after injection. The ECG 
strip below shows ECG waveforms of a normal control rat injected with saline. In contrast to the control rat, PR intervals were 










Fig. 3.29 Type I second-degree AV block or AV Wenckebach block  
The top and bottom ECG strips reveal type I second-degree AV blocks whereby lengthening of PR intervals (arrows) 
proceeded until one P wave was left out. After the blocked P wave, the next PR interval returned back to normal and the cycle 
repeated itself. In contrast to the type I second-degree AV blocks exemplified in the top and bottom strips, the middle ECG strip 


















Fig. 3.30 Type II second-degree AV block, Mobitz type II 
  Type II second-degree AV block was presented as regularly omitted QRS waves at fairly consistent intervals. The PR intervals 
of conducted beats were constant with no change in duration. (A) The top ECG strip reveals a type II second-degree AV block with 
skipped beats for about every 5 impulses. (B) The ECG strip below demonstrates similar type II AV block with blocked P waves 













Fig. 3.31 Torsades de pointes ventricular tachycardia 
  (A) The characteristic undulating, spindle appearance of TdP is displayed and a long pause (arrows) typically appeared before 
the tachycardia. Episodes of TdP were followed by either AV blocks or consecutive prolongations between impulses as shown.  (B) 









Fig. 3.32 Arrhythmias preceding onset of TdP and between episodes of TdP 
 (A) Short-long ECG cycles were frequently seen preceding onset of TdP. They appeared amidst recurrent episodes of the 
malignant ventricular tachyarrhythmia as well. (B) The upper ECG strip shows repetitive large, immense prolongations between the 
QRS complexes in contrast to the first degree AV block recorded in a second rat in the lower ECG strip. The RR interval of the upper 
strip was calculated to be 800 ms while that in the lower strip was 168 ms. Both types of arrhythmias were observed between episodes 
of TdP. 
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In the two rats that died from 1 LD50 VX poisoning, ventricular flutter and 
ventricular fibrillation occurred prior to cessation of the beating of heart. Ventricular 
flutter and ventricular fibrillation were severe derangements of the cardiac electrical 
rhythm that were associated with hemodynamic collapse and without prompt 
intervention, usually resulted in death. Fig. 3.33 reveals ventricular flutter whereby 
QRS and T waves formed regular, zigzag, oscillating pattern (sinusoidal 
morphologic appearance). Fig. 3.33A demonstrates a short period of the ventricular 
flutter that interrupted the serious sinus bradycardia which was marked by long 
lengthening periods between the QRS complexes. Fig. 3.33B reveals sustained 
ventricular tachycardia of the ventricular flutter type which was potentially life-
threatening. The ventricular arrhythmia manifested prior to 4 minutes and 1 minute 
prior to the termination of heart activity in the two rats. 
 
 Occurrence of ventricular fibrillation followed soon after ventricular flutter in 
two rats. Different parts of the ventricles depolarised and contracted repeatedly in an 
erratic and uncoordinated fashion as a result of numerous impulses initiated by 
multiple ectopic foci. The chaotic electrical activity in the ventricles was represented 
by random unrelated ECG traces with no identifiable ventricular complexes. Fig. 3.34 
reveals the fibrillatory waves with amplitudes of very low magnitude. The animals 
died within a minute after onset of the fatal ventricular fibrillation due to the 
uncoordinated contractions of ventricular myocardium resulting in ineffective 












Fig. 3.33 Ventricular flutter in 1 LD50 VX challenged rat 
 (A) Ventricular flutter (arrow) was observed among severe impulse prolongations. As compared to the severe sinus 
bradycardia which flanked the brief ventricular tachycardia, normal pronounced QRS complexes and P waves were absent in 
ventricular flutter. (B) Continuous ventricular flutter was recorded at 76 minutes post injection in one of the rats which died shortly 















Fig. 3.34 Ventricular fibrillation prior to termination of heat beat 
 The bizarre, irregular and random waveforms distinctive of ventricular fibrillation were demonstrated by two rats which died 
from 1 LD50 VX. No recognisable QRS complexes were detected during the event of ventricular fibrillation. There is a QRS complex 
(arrow) in the ECG tracing and the extremely low amplitude of the fibrillatory waveforms in ventricular fibrillation can be compared 








3.2.6.2 Post exposure - 14 days  
 
3.2.6.2.1    Physiologic and electrocardiographic data 
 
 ECG measurements were subsequently carried out up to day 14 post 1 LD50 
VX challenge. Table 3.6 summarises the physiologic and electrocardiographic data 

































Table 3.6 Physiologic and electrocardiographic parameters for 14 days post 1 LD50 VX injection 
 










PR interval (ms) 
Baseline 450 ± 21 37.7 ± 0.3 94 ± 6 135 ± 6 0.254 ± 0.011 42.4 ± 1.2 
Day 1 374 ± 14* 35.4 ± 1.9 124 ± 5* 165 ± 4* 0.306 ± 0.008* 42.9 ± 0.6 
Day 2 368 ± 6* 37.1 ± 0.8 127 ± 5* 171 ± 7* 0.308 ± 0.006* 44.4 ± 3.2 
Day 3 388 ± 10 37.6 ± 0.6 121 ± 1* 163 ± 2* 0.300 ± 0.003* 43.1 ± 1.2 
Day 4 416 ± 18 37.7 ± 0.8 120 ± 10 163 ± 9* 0.297 ± 0.016 43.6 ± 1.9 
Day 5 411 ± 11 37.6 ± 0.8 116 ± 4 159 ± 3* 0.291 ± 0.008 43.1 ± 0.4 
Day 6 430 ± 13 37.7 ± 0.8 117 ± 4* 159 ± 3* 0.293 ± 0.008 44.9 ± 0.4 
Day 7 414 ± 28 37.6 ± 0.6 120 ± 4* 163 ± 5* 0.296 ± 0.005* 45.3 ± 1.3 
Day 8 427 ± 19 37.9 ± 0.9 117 ± 9 161 ± 11 0.292 ± 0.012 45.8 ± 1.2 
Day 9 409 ± 25 37.8 ± 0.8 117 ± 8 161 ± 8* 0.292 ± 0.014 44.9 ± 0.4 
Day 10 419 ± 31 37.7 ± 0.9 119 ± 11 160 ± 11 0.296 ± 0.018 44.4 ± 1.6 
Day 11 399 ± 35 37.6 ± 0.9 133 ± 8* 178 ± 10* 0.315 ± 0.009* 46.2 ± 1.2 
Day 12 433 ± 26 38.3 ± 0.8 121 ±10 163 ± 13 0.299 ± 0.013* 45.3 ± 1.3 
Day 14 425 ± 26 38.1 ± 0.8 121 ± 8* 164 ± 10* 0.299 ± 0.012* 45.8 ± 0.9 
Values represent means ± SEM; n = 3. 
* P < 0.05; ** P < 0.005; *** P < 0.001
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 The average heart rate of the animals remained significantly low on day 1 and 
day 2 after exposure to 1 LD50 VX (P < 0.05). The basal heart rate of 450 ± 21 beats 
per minute decreased the most on day 2 by 18.2%. Recovery of the heart rate took 
place on the third day post injection with the normal heat rate being nearly restored 
on day 4 and day 5. Thereafter, the heart rate of the poisoned animals normalised to 








































































Fig. 3.35 Heart rate of animals for 14 days post 1 LD50 VX exposure 
 The average heart rate decreased significantly on day 2 and day 3. However, 
recovery of the heart rate began from the fourth day onwards. Subsequently, the 
normal heart rate was not statistically different from the basal heart rate. Values were 
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 Compared to the mean body temperature before exposure, the mean body 
temperature of the animals decreased notably on day 1 post injection (Fig. 3.36). 
Although there was a drop of 2.3 °C or decrease of 6.1% on day 1, it was not a 
substantial decrease according to the statistical calculations. The mean body 
































































Fig. 3.36 Body temperature of animals for 14 days post 1 LD50 VX exposure 
 The decrease in the average body temperature was still evident a day after 
injection. Although not statistically significant, the 2.3 °C drop in temperature was 
can be seen clearly in the graph. The animals regained normal body temperatures 







 Both QT and RR intervals were prolonged in duration in the 14 days 
following exposure. Computation revealed extension of mean QT intervals on day 1, 
2, 3, 6, 7, 11 and 14 to be significant (all P < 0.05). Fig. 3.37 shows the greatest QT 
duration extension on day 11, from baseline value of 94 ± 6 ms to 133 ± 8 ms 
(41.5%). Prolongation of RR interval verified the existence of bradycardia in the 
animals, with statistically significant values on 10 out of the 14 days (all P < 0.05). 
Maximum RR interval was observed on day 11, with an increase of 31.9% from 135 











































Fig. 3.37 Mean QT interval for 14 days following 1 LD50 VX exposure 
 QT intervals were statistically significantly prolonged on day 1, 2, 3, 6, 7, 11 
and 14 from the baseline value of 94 ± 6 ms. The greatest extension in QT duration 
occurred on day 11 to 133 ± 8 ms, which was translated into an increase of 41.5%. 
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Fig. 3.38 Mean RR interval for 14 days following 1 LD50 VX exposure 
 Duration between each heart beat was shown to be augmented for 14 days 
post exposure. Statistical computation revealed significant values on day 1, 2, 3, 4, 5, 
6, 7, 9, 11 and 14. The mean basal RR duration was 135 ± 6 ms and it hit a highest 
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 Prolongation of mean QTc interval over 14 days is illustrated in Fig. 3.39 with 
significant values on day 1, 2, 3, 7, 11, 12 and 14 (all P < 0.05). Statistically 
important QTc interval lengthening was maintained for consecutive 3 days following 
VX exposure before dropping slightly. The least amount of increase in QTc duration 
was recorded on day 5 with an increase of 14.6% from baseline of 0.254 ± 0.011 
seconds to 0.291 ± 0.008 seconds. Statistically significant prolongation returned again 
on day 7 and the last three days of observation. QTc interval lengthening peaked on 





























































Fig. 3.39 QTc interval for 14 days post 1 LD50 VX exposure 
 The mean QTc interval was lengthened after 1 LD50 VX challenge for 14 
days, with statistical significant values on day 1, 2, 3, 7, 11, 12, 14. The amplification 
in QTc duration was the greatest on day 11 with an increase of 24.0% from the 
baseline. Values were expressed as means ± SEM; n = 3; * P < 0.05. 
 * * 
  *  * 
* 
 *   * 
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 The PR interval, representing the length of time required for each impulse to 
travel from the atria to the ventricles, was slightly prolonged from its baseline value 
in the 14 days post injection (Fig. 3.40). According to statistical analysis, the slight 
increase in time duration was not significant. Nonetheless, the nominal increase in PR 
interval persisted up to day 14. As in other electrocardiographic parameters, the 
largest increase in duration was observed on day 11, from a basal value of 42.4 ± 1.2 





























































Fig. 3.40 Mean PR interval for 14 days after 1 LD50 VX injection 
 Although the augmentation in PR duration was computed as statistically 
insignificant, the persistent slight prolongation was evident from the graph. It was 
sustained for 14 days post VX challenge. Values were expressed as means ± SEM; n 








3.2.6.2.2 Cardiac rhythm 
 
 Marked sinus bradycardia with clearly identifiable QT prolongation was 
observed in the animals on day 1 and 2 post 1 LD50 VX exposure. Lengthening of the 
QT intervals was followed occasionally by periods of TdP of various durations on 
day 1. Similar to the day on which the acute dose of VX was given, the TdP was 
preceded by series of ECG waveforms in which QT intervals were significantly 
extended. Fig. 3.41 shows typical prolongation of the QT intervals which predisposed 
the animals to episodes of TdP. Although TdP manifested only on day 1 post 
challenge, lengthening of QT duration appeared consistently during the 14 days of 
recording.  
 
 Second-degree AV blocks of type I and II were also observed in the animals 
up to day 14. On Day 4, short-long ECG cycles appeared spontaneously and were 
detected daily up to day 14. The short-long cycles appeared among regularly-paced 
waveforms and were reproducible frequently. The RR intervals of short cycles ranged 
from 92 to 100 ms while the RR intervals of the long cycles that instantaneously 
tailed the short cycles lasted from 148 to 164 ms. Fig. 3.42 displays the distinctive 
and usual short-long cycles that were recorded in the animals.  
 
 Arrhythmias observed in the 14-days period post exposure also included 
isolated sustained prolongations between the ECG waveforms. The intense 
prolongations started appearing on day 2 and were detected until day 14. The 
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lengthening between cycles were either clustered in groups (Fig. 3.43A) or 
manifested as extreme solitary individual prolongations (Fig. 3.43B). The duration of 
single prolongation tended to be longer (296 ms to 456 ms) compared to that 














Fig. 3.41 QT interval prolongation  
 Lengthening of the distance from the beginning of the ventricular complex to the end of the T wave is evident in the ECG 
tracings of rat that had been administered with 1 LD50 VX, shown in the top panel. The tracing in the bottom panel was recorded in a 
control rat. No extension of the QT interval was present. The QT interval of the control that is shown here averaged at 92 ms while 

















Fig. 3.42 Short-long ECG cycles among regular waveforms 
 Arrhythmia observed in the 14 days post 1 LD50 VX challenge included short-long cycles which recurrently appeared between 
regularly paced waveforms. The ECG strip shows the short-long cycles present every 4 to 5 normal cycles. The RR duration of the 

























Fig. 3.43 Intense ECG cycle prolongations  
 Long-lasting lengthening of the ECG waveforms surfaced on day 2 and were presented either (A) in clustered, or (B) as a 
solitary prolongation. The gathering of clustered prolongations in (A) ranged from 240 ms to 320 ms while the solitary prolongation 
shown in (B) lasted for 456 ms. The ECG cycle that trailed directly after the solitary prolongation was slightly extended in duration to 









3.3 CHRONIC 0.4 LD50 VX INJECTIONS 
3.3.1 Clinical observations after injection 
 
 A total of 24 rats were administered with 0.4 LD50 VX (s.c.) daily up to 8 days 
using a Monday through Friday injection regimen. No drug treatment was given and 
all animals survived. The number of animals experiencing the clinical signs and 
symptoms of poisoning following injection of VX are tabulated in Table 3.7.  
 
 On the first day after the rats received the first injection of 0.4 LD50 VX, all 
animals demonstrated mastication or chewing motions within an average of 25 
minutes. The time taken for the onset of mastication was comparatively longer in 
contrast to that taken for the manifestation of mastication following 1.6 LD50 and 1 
LD50 VX, which were 5 and 12 minutes respectively. Tremors of the facial muscles 
were also seen in 16 out of 24 rats (66.67%). Second administration of 0.4 LD50 VX 
on the following day resulted in mastication appearing after 15 minutes on average in 
all animals. The shorter onset taken for the appearance of mastication was 
accompanied by a higher percentage of rats exhibiting facial tremors (83.33%). In 
addition, 44.44% of rats had weakness in the hind legs and were prostrate. More 
clinical symptoms of poisoning included body tremors, diarrhoea and exophthalmos 
which had a similar occurrence of 5.56%.  
 
 Mastication appeared by 10 minutes in 94.4% of the rats following injection 
on the third day of 0.4 LD50 VX dosing. These animals also demonstrated facial 
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tremors. Twelve of the 18 rats (66.67%) were prostrate while body tremors and 
exophthalmos occurred in 5 (27.78%) and 2 rats (11.11%) respectively. Clonic 
movements of the head, forepaw and face were observed for the first time in the rats 
(16.67%). On the fourth and fifth days of dosing, 100% of the animals showed 
masticatory movements and facial tremors. Mastication took around 10 minutes to 
appear on both days. 91.67% and 100% of the rats were prostrate on the fourth and 
fifth days of dosing respectively. Tremors of the whole body musculature and head 
clonic movements were observed in 75% and 25% of the rats on day 4 of dosing 
while 100% of the rats exhibited these symptoms on day 5. Moreover, tonic-clonic 
convulsions were observed for the first time in one of the rats on day 5. 75% and 
100% of the animals had protrusion of the eyeballs on day 4 and 5.  
 
 The sixth dose of 0.4 LD50 VX was given two days after the fifth dose on day 
5 due to the Monday through Friday injection regimen. Nonetheless, all animals 
showed mastication and tremors in the facial muscles. 50% of the animals were 
prostrate and 66.67% had body tremors. Only 1 out of 6 animals had face, forepaw 
and head clonuses. As in the first 5 days of injection, the symptoms of intoxication 
increased in severity with a higher percentage of animals demonstrating more severe 
symptoms from day 6 until day 8 of injection. Furthermore, progression in the 
severity and frequency of the clinical symptoms of poisoning occurred at a more 
rapid rate compared to the first 5 days of dosing. Tonic-clonic convulsions and straub 
tails were seen in 5 of the 6 rats (83.33%) on day 8 and 50% lost righting reflex at 
some point during the convulsions.  
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 The control rats which were given saline solution injections displayed no 
symptoms of poisoning. 
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Table 3.7 Clinical observations after s.c. injection of 0.4 LD50 VX 
    No. of  rats    
Observations Day 1 
(n = 24) 
Day 2 
(n = 18) 
Day 3 
(n = 18) 
Day 4 
(n = 12) 
Day 5 
(n = 6) 
Day 6 
(n = 6) 
Day 7 
(n = 6) 
Day 8 
(n = 6) 
Mastication (chewing movements) 24 18 17 12 6 6 6 6 
Facial tremors 16 15 17 12 6 6 6 6 
Hind limb weakness and prostration 0 8 12 11 6 3 4 6 
Whole body tremors 0 1 5 9 6 4 5 6 
Facial, forepaw and head clonus 0 0 3 3 6 1 5 5 
Tonic-clonic convulsions 0 0 0 0 1 0 2 5 
Straub-tail 0 0 0 0 1 0 1 5 
Diarrhoea 0 1 0 0 0 1 2 1 
Loss of righting reflex 0 0 0 1 0 0 1 3 
Salivation 0 0 0 1 2 0 0 1 
Lacrimation 0 0 0 2 1 0 0 1 
Exophthalmos 0 1 2 9 6 2 5 6 
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3.3.2 Weight profile 
 
 Animals were weighed daily before administration of VX or saline solution. 
Mean weight of the rats that received chronic dosing of 0.4 LD50 VX was 208.79 ± 
2.54 g prior to injection on dosing day 1. As shown in Fig. 3.44, daily injections of 
0.4 LD50 VX resulted in slight but progressive weight loss in the rats in the first 5 
days of dosing. Analysis via statistical computation indicated the mean weight to be 
considerably reduced 24 hours after the first dose of 0.4 LD50 VX was administered 
(P < 0.05). Weight reduction was more significant on dosing days 3, 4 and 5 (all P < 
0.001). Greatest weight loss occurred on the fifth day of dosing with the average 
weight of the VX-challenged rats decreasing by 7.96g or 3.81% to 200.83 ± 3.40 g. 
Weights of the rats were regained on the following Monday before the sixth injection 
was given. Although there was a slight decrease in weight on dosing day 7, it was 
statistically insignificant. The average weight of the VX-exposed rats was maintained 
through the last day of injection i.e. dosing day 8 up till 5 days after that.   
 
 In contrast, the control rats which received saline solution injections exhibited 






















































































































Fig. 3.44 Mean weights of rats subjected to chronic injections of 0.4 LD50 VX and 
control rats 
 Rats challenged with chronic administration of 0.4 LD50 VX received VX 
injections daily for 8 days and the control rats were injected correspondingly with 
saline solution. VX-challenged rats (♦, n = 24) displayed weight loss in the first 5 
days of VX administration. However, weight loss was not significant in the following 
week of VX injections. Mean weight was maintained at around 225 g for 5 days after 
the last injection was given on dosing day 8. The control rats (■, n = 6) displayed 
normal body weight gain all through the 13 days. Values are presented as means ± 
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3.3.3 Acetylcholinesterase activity 
 
 Measurement of AChE activity 24 hours after administration of the first dose 
of 0.4 LD50 VX revealed a drop of 43.71% from a basal level of 4.244 ± 0.071 U/gHb 
to 2.389 ± 0.232 U/gHb (P < 0.001). Subsequent injections on a daily basis resulted 
in further decrease in enzyme activity (Fig. 3.45). AChE activity reached the lowest 
of 1.496 ± 0.078 U/gHb (P < 0.001) on the last day of dosing i.e. dosing day 8. 
Although enzyme activity recovered to 2.977 ± 0.337 U/gHb 5 days after the last VX 
administration of the chronic regimen, it was still statistically significantly lesser than 



















































Fig. 3.45 Blood acetylcholinesterase activity of 0.4 LD50 VX-exposed rats and 
control rats 
 Baseline AChE activity was the original enzyme activity before the rats 
started with the chronic regimen. As shown in the graph, chronic administration of 
0.4 LD50 VX to the rats (♦, n = 24) gave rise to a gradual decline in AChE activity up 
till the last day of injection (all P < 0.001). 5 days after the last injection on dosing 
day 8, assay of whole blood from VX-challenged rats was again carried out. 
Difference from the baseline value was computed as statistically significant at P < 
0.005. Enzyme activities of control rats (■, n = 6) were not changed significantly. 













   *** 
  *** 
  *** 
  *** 
   ** 
 145 
3.3.4 Histopathological changes  
 
 Perfusion of the rats was carried out 24 hours following first, third, fourth and 
eighth 0.4 LD50 VX injections. Histological scores of the organs examined are 
displayed in Table 3.8.  
 
 Control animals which received saline injections for the 8 dosing days 






























Table 3.8 Incidence and severity of histopathological changes in rats subjected to 
chronic dosing regimen of 0.4 LD50 VX  
 
Heart Kidney Skeletal 
Muscle 
Lungs Liver 
Dosing day 1      
DD1 rat 1  0 0 0 0 0 
DD1 rat 2  0 0 0 0 0 
DD1 rat 3 0 0 0 0 0 
DD1 rat 4 0 0 0 0 0 
DD1 rat 5 0 0 0 0 0 
DD1 rat 6 0 0 0 0 0 
Dosing day 3      
DD3 rat 1  0 1 0 0 0 
DD3 rat 2  0 0 0 0 0 
DD3 rat 3  0 0 0 0 0 
DD3 rat 4 0 0 0 0 0 
DD3 rat 5 0 0 0 0 0 
DD3 rat 6 0 0 0 0 0 
Dosing day 4      
DD4 rat 1  1 0 0 0 0 
DD4 rat 2  0 0 0 0 0 
DD4 rat 3  0 0 0 0 0 
DD4 rat 4 1 1 1 0 0 
DD4 rat 5 1 0 0 0 0 
DD4 rat 6 1 1 1 0 0 
Dosing day 8      
DD8 rat 1 (C) 0 0 0 0 0 
DD8 rat 2 (C) 1 0 2 1 0 
DD8 rat 3 (C) 2 1 0 2 0 
DD8 rat 4 1 0 0 0 0 
DD8 rat 5 (C) 1 0 0 0 0 
DD8 rat 6 (C) 1 0 0 0 0 
(C) – tonic-clonic convulsions present; grade 0 – nil (0%); grade 1 – minimal (1-10%); 
grade 2 – mild (11-25%); grade 3 – moderate (26-45%) and grade 4 – severe (>45%)  
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3.3.4.1 Cardiac muscle 
 
 Myocardial damage was only detected from the fourth day of injection 
onwards. Of the 6 animals perfused 24 hours after administration of the fourth dose of 
0.4 LD50 VX, 4 animals showed myocardial injury. Myocardial injury was also 
observed in 5 out of 6 animals examined 24 hours after dosing day 8. The extent of 
damage was minimal, with the exception of 1 rat which had mild myocardial damage 
of grade 2. Myocardial changes were similar to those observed in rats challenged with 
acute doses of 1.6 LD50 and 1 LD50 VX, only difference being the cardiac injuries 
found in this group as less severe and extensive. Infiltration of inflammatory 
mononuclear cells and small areas of myofibre necrosis were typically seen.  
Interstitial deposition of amorphous necrotic debris and neutrophils occasionally 
surrounded the necrotic cardiac cells. As in the cardiac damage observed in the 1.6 
LD50 and 1 LD50 VX groups of rats, the cardiac lesions were multifocal and 
dominated in the interventricular septa, left ventricles and papillary muscles.  
   
3.3.4.2 Kidney 
 
 Histopathological changes of the kidneys were not frequently seen in the 
animals. Only one rat each in the dosing day 3 and 8 sets of rats and 2 rats from the 
dosing day 4 set of rats were detected with minimal renal changes. The form of renal 
histological injury observed was akin to that discovered previously in rats challenged 
with 1.6 LD50 and 1 LD50 VX. Small hyperaemic areas, comprising of assemblages of 
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red blood cells, distributed randomly in the interstitial region between the tubules, 
renal corpuscles and medullary rays. Present in all 4 rats with renal morphological 
changes, the areas of red blood cell congestion were located in the cortex and outer 
medulla. Histological sections from 1 rat showed infiltration of polymorphonuclear 
cells.  
 
3.3.4.3 Skeletal muscle 
 
 Gastrocnemius and biceps femoris muscle fibres of most rats were normal in 
cellular morphology and structure. Only 3 of the 24 rats examined had injuries in the 
skeletal muscles. Muscle damage was minimal in 2 rats which received four 
injections of 0.4 LD50 VX while the injury was mild in 1 rat which received eight 
injections. Muscle lesions were similar to that evaluated in the 1.6 LD50 and 1 LD50 
VX groups of rats. Affected regions were presented as small multifocal areas 
permeated with mononuclear cellular bodies. Necrotic myofibrils were also found 




 Pulmonary inflammatory changes were rarely observed in the 0.4 LD50 VX - 
exposed rats. Merely 2 rats from the batch of rats which were administered with eight 
injections showed minimal to mild injury of the lungs. Interstitial leukocytic 
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infiltrates as well as pulmonary congestion within capillaries of the alveolar walls 




 None of the rats exposed to the chronic doses of 0.4 LD50 VX showed any 
visible histological damages.  
 
3.3.5 Correlation between cardiac damage and convulsions 
 
 Evaluation of the prevalence and severity of cardiac injury revealed poor 
relationship between tonic-clonic convulsive activity and cardiac damage. Although 
no rats experienced any convulsion episodes following the fourth injection, 4 out of 6 
rats (66.67%) perfused 24 hours later showed minimal cardiac damage.  
 
 Tonic-clonic convulsive activity first appeared after the fifth injection was 
given on the fifth day of dosing in DD8 rat 2.  On the seventh day of injection, 2 rats 
(DD8 rat 1 and 2) were presented with the convulsions. All but one rat i.e. DD8 rat 4 
experienced convulsions on the eight day of dosing. No histopathological light 
microscopic changes were observed in DD8 rat 1 which underwent two episodes of 
convulsions on dosing day 7 and 8 while DD8 rat 2 which experienced the 
convulsions on three occasions following VX administration had only minimal 
cardiac damage. In comparison, DD8 rat 3 which had only one convulsion attack after 
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receiving the eight injection was presented with the greatest amount of cardiac injury 
among the 24 rats subjected to the chronic regimen. Furthermore, the only rat in the 
dosing day 8 group that did not had convulsions presented minimal injury in the 























3.3.6.1 Physiologic and electrocardiographic data 
 
   
 Surgical implantations of the TSE telemetry transmitters were carried out in 8 
rats and the animals were subjected to repetitive injections of 0.4 LD50 VX once a day 
over a period of 8 days. ECG recordings were done before the first injection on 
dosing day 1 to derive the basal physiologic and electrocardiographic values which 
were then subsequently used for reference to the readings taken after the animals had 
been intoxicated with VX.  
 
 As in the 1 LD50 VX batch of animals, each session of recordings were carried 
out for 120 minutes post injection. Similarly, the physiological parameters measured 
included heart rate and body temperature while the electrocardiographic parameters 
analysed were QT interval, RR interval, QTc interval and PR interval.  The data is 
summarised in Table 3.9.  
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Table 3.9 Effects of chronic 0.4 LD50 VX administration on physiologic and electrocardiographic parameters 
 













Baseline (n = 8) 453 ± 8 38.0 ± 0.1 91 ± 3 131 ± 2 0.250 ± 0.005 39.8 ± 0.9 
DD 1 (n = 8) 353 ± 8*** 36.5 ± 0.4** 130 ± 3*** 174 ± 4*** 0.310 ± 0.005*** 46.7 ± 2.7* 
DD 2 (n = 8) 310 ± 13*** 33.8 ± 0.5*** 148 ± 7*** 199 ± 8*** 0.331 ± 0.009*** 53.2 ± 1.9*** 
DD 3 (n = 8) 275 ± 18*** 33.1 ± 0.5*** 173 ± 14*** 230 ± 16*** 0.357 ± 0.017*** 59.2 ± 2.4*** 
DD 4 (n = 8) 254 ± 12*** 33.1 ± 0.5*** 192 ± 12*** 254 ± 14*** 0.379 ± 0.014*** 63.2 ± 2.6*** 
DD 5 (n = 6) 257 ± 15*** 33.2 ± 0.6*** 192 ± 19*** 252 ± 21*** 0.380 ± 0.020*** 59.8 ± 2.3*** 
DD 6 (n = 6) 344 ± 13*** 34.7 ± 0.7*** 134 ± 5*** 179 ± 7*** 0.315 ± 0.008*** 49.3 ± 2.5** 
DD 7 (n = 6) 299 ± 22*** 33.6 ± 0.7*** 178 ± 20*** 234 ± 26*** 0.366 ± 0.020*** 58.4 ± 5.4** 
DD 8 (n = 6) 285 ± 10*** 33.3 ± 0.5*** 173 ± 6*** 226 ± 10*** 0.364 ± 0.005*** 52.9 ± 4.0** 
1 day post DD 8 (n = 6) 376 ± 8*** 37.2 ± 0.2* 132 ± 4*** 173 ± 4*** 0.318 ± 0.005*** 40.4 ± 1.5 
2 days post DD 8 (n = 4) 400 ± 6** 37.2 ± 0.2* 123 ± 4*** 166 ± 6*** 0.302 ± 0.005*** 44.7 ± 3.1 
3 days post DD 8 (n = 4) 405 ± 22* 37.6 ± 0.4 117 ± 7*** 158 ± 8** 0.295 ± 0.010** 42.0 ± 2.2 
4 days post DD 8 (n = 4) 409 ± 15* 37.2 ± 0.3* 126 ± 6*** 168 ± 6*** 0.308 ± 0.009*** 43.7 ± 0.8* 
5 days post DD 8 (n = 4) 408 ± 6** 37.4 ± 0.4 136 ± 3*** 179 ± 4*** 0.321 ± 0.004*** 43.3 ± 1.2* 
DD represents dosing day. Values represent means ± SEM. 
* P < 0.05; ** P < 0.005; *** P < 0.001 
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 Basal heart rate of the animals averaged at 453 ± 8 beats per minute prior to 
commencement of the chronic VX challenge. After receiving the first 0.4 LD50 VX 
injection, mean heart rate of the animals significantly decreased by 22.1% to 353 ± 8 
beats per minute (P < 0.001). Further reduction of the average heart rate was noted in 
the subsequent days of injection and significant reduction at P < 0.001 was observed 
throughout the 8 days of injections. Fig. 3.46 shows the low heart rates induced by the 
chronic exposure. One day after the administration of the last dosage, the average 
heart rate remained reduced at a significant level of less than 0.001. It slightly 
recovered but still remained notably suppressed on the fifth day post injection (P < 
0.005).  
 
 Injection of 0.4 LD50 VX resulted in a drop in body temperature on the first 
day of dosing from an original mean of 38.0 ± 0.1 °C to 36.5 ± 0.4 °C (P < 0.005). 
Continued dosing augmented the drop to P < 0.001 (Fig. 3.47). The mean body 
temperature of the animals was regained to a significant level of less than P < 0.05 on 
day 1, 2 and 4 post final injection. Measurement of the body temperatures of the 
animals 5 days after administration of the last 0.4 LD50 VX injection showed no 















































































































































Fig. 3.46 Mean heart rate upon chronic administration of 0.4 LD50 VX  
 Exposure to VX resulted in a drop in heart rate from the first day of injection. 
It was further brought down in the consecutive days of injection until dosing day 5. 
Slight regaining of heart rate observed on the sixth day of injection was due to a two-
day break in the Monday to Friday dosing regimen. The heart rate was, nevertheless, 
still greatly reduced at P < 0.001. Recovery of the heart rate to its initial status was 
not observed at 5 days post last injection. All values are presented as means ± SEM (n 
= 8 on dosing day 1 to dosing day 4; n = 6 on dosing day 5 to day 1 post dosing day 
8; n = 4 on day 2 post dosing day 8 to day 5 post dosing day 8). * P < 0.05; ** P < 
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Fig. 3.47 Mean body temperature of animals chronically injected with 0.4 LD50 
VX 
 Repeated administration of 0.4 LD50 VX brought about significant decrease in 
average body temperature of the rats. The greatest drop in body temperature was 
observed on the third and fourth day of dosing, from an original baseline value of 
38.0 ± 0.1 °C to 33.1 ± 0.5 °C (by 12.9%). Decrease in mean body temperature at 
statistical significant level of P < 0.001 was shown from the second to the last day of 
the chronic regimen. Recovery of the basal temperature was observed in the rats 5 
days following completion of the chronic dosing regimen. All values are presented as 
means ± SEM (n = 8 on dosing day 1 to dosing day 4; n = 6 on dosing day 5 to day 1 
post dosing day 8; n = 4 on day 2 post dosing day 8 to day 5 post dosing day 8). * P < 
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 Prolongation of the average QT interval (Fig. 3.48) and RR interval (Fig. 
3.49) was evident from the first day of injection up to 5 days after the last day of 
injection. Throughout the 13 days, mean basal QT interval of 91 ± 3 ms was 
lengthened to a large extent (all P < 0.001). The greatest increase in QT duration that 
occurred on the fifth day of injection was more than one fold or 111.0% of the basal 
value at 192 ± 19 ms. Mean RR intervals were also extended significantly at P < 
0.001 for 12 days.  The only exception was on day 3 post injection day 8 where the 
difference in RR duration from that at basal was lesser at P < 0.005. Elevation from 
basal RR interval (131 ± 2 ms) was the largest on dosing day 4 at 254 ± 14 ms by 
93.9%.  
 
 Resembling the physiologic data, both mean QT and RR intervals were 
recovered to some extent on dosing day 6. This was due to the two-day break in the 
Monday to Friday dosing regimen. Nonetheless, the intervals remained extended in 
































































































































Fig. 3.48 Mean QT interval of animals administered with chronic doses of 0.4 
LD50 VX  
 Compared to the average basal QT interval at 91 ± 3 ms, mean QT intervals 
were significantly extended in duration during the 8 days of injection and 5 days after 
completion of the chronic injection routine (all P < 0.001). The duration remained 
prolonged at an average of 136 ± 3 ms by 49.5% of the original value even on day 5 
after the last day of injection (P < 0.001). All values are presented as means ± SEM 
(n = 8 on dosing day 1 to dosing day 4; n = 6 on dosing day 5 to day 1 post dosing 
day 8; n = 4 on day 2 post dosing day 8 to day 5 post dosing day 8). * P < 0.05; ** P 
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Fig. 3.49 Mean RR interval of animals given chronic 0.4 LD50 VX injections 
 Daily injections of low doses of 0.4 LD50 VX resulted in extended RR 
intervals on the 8 dosing days on which injections were given and for the following 5 
days. Only the mean RR interval on day 3 post injection day 8 was statistically 
different from the baseline value at P < 0.005 while mean RR intervals on the 
remaining 12 days were elevated at P < 0.001. All values are presented as means ± 
SEM (n = 8 on dosing day 1 to dosing day 4; n = 6 on dosing day 5 to day 1 post 
dosing day 8; n = 4 on day 2 post dosing day 8 to day 5 post dosing day 8). * P < 
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 Significant increase in duration of mean QTc interval was observed in 
poisoned rats during the 8 days of 0.4 LD50 VX administrations (all P < 0.001). In 
addition, QTc prolongation at a statistical significance level of P < 0.001 was noted 
on day 1, 2, 4 and 5 after completion of the chronic injection regimen. As shown in 
Fig. 3.50, the greatest augmentation in duration occurred on dosing day 5 where the 
basal mean of 0.250 ± 0.005 seconds increased by 52% to 0.380 ± 0.020 seconds. 
 
 Animals injected with low doses of VX also demonstrated substantial 
prolongation of PR interval all through the 8 days of chronic dosing. By day 1 of 
injection, mean basal PR interval of 39.8 ± 0.9 ms had increased to 46.7 ± 2.7 ms (P 
< 0.05) and the increment reached statistical significant level of P < 0.001 on dosing 
day 2, 3, 4 and 5 subsequently (Fig. 3.51). Significant prolongation was again 






































































































































Fig. 3.50 Mean QTc interval of animals injected with chronic doses of 0.4 LD50 
VX 
 Mean QTc interval of animals that were injected with 0.4 LD50 VX on a daily 
basis was lengthened from a baseline value of 0.250 ± 0.005 seconds up to 0.380 ± 
0.020 seconds on the fifth day of injection (P < 0.001). Statistical analysis revealed 
persistence in the QTc interval prolongation up to 5 days after the last injection was 
given (P < 0.001). All values are presented as means ± SEM (n = 8 on dosing day 1 to 
dosing day 4; n = 6 on dosing day 5 to day 1 post dosing day 8; n = 4 on day 2 post 
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Fig. 3.51 Mean PR interval of animals administered with chronic doses of 0.4 
LD50 VX 
 Duration of mean PR interval of the VX-challenged rats was lengthened 
during the period of chronic dosing. Despite recovery on day 1, 2 and 3 after the last 
day of injection, PR interval prolongation reappeared on day 4 and 5 after injection 
day 8 (P < 0.05). All values are presented as means ± SEM (n = 8 on dosing day 1 to 
dosing day 4; n = 6 on dosing day 5 to day 1 post dosing day 8; n = 4 on day 2 post 
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3.3.6.2 Cardiac rhythm 
 
 Sinus bradycardia with marked QT prolongation was evident from the first 
day of injection to the last day of observation in all rats. After injection of the first 
dose of 0.4 LD50 VX on dosing day one, one rat had exhibited cardiac arrhythmias 
(Table 3.10). By day 2 after the second dose was administered, 50% of the rats had 
cardiac rhythm abnormalities. The proportion of rats presented with cardiac 
arrhythmias increased to 75% on the third dosing day. Thereafter, cardiac arrhythmias 
was observed in all intoxicated rats after receiving 0.4 LD50 VX injections on dosing 
day 4, 5, 7 and 8. Only one rat did not display arrhythmias on dosing day 6, bringing 
down the occurrence of arrhythmias to 83.33%. The drop in arrhythmia incidence on 
dosing day 6 was probably a result of a two-day break in the Monday to Friday 
dosing regimen. 
 
 Irregularities in the cardiac rhythm persisted up to 5 days after completion of 
the chronic injection regimen. As shown in Table 3.10, 66.67% of the VX-challenged 
rats had reproducible cardiac arrhythmias 24 hours following the last injection on 
injection day 8. On day 2 and 3 after the last day of exposure, ECG recordings 
showed arrhythmias in 50% of the rats. The percentage of rats detected with 
arrhythmias increased to 75% on day 4 and 5 post dosing day 8. 
 
 Cardiac arrhythmias detected in the chronically dosed rats included first-
degree AV block and second-degree AV blocks of type I and II. Short-long ECG 
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cycles appearing spontaneously amid regular waveforms were most commonly 
observed. Repetitive extreme pauses or prolongations were also reproducible up to 
day 5 following the last day of injection. The intensity and frequency of the ECG 
abnormalities were observed to be greater during the days of injection compared to 
the 5-days duration after the last of the chronic injections. No animal was presented 
with TdP throughout the 13 days.  
 
 Tonic-clonic convulsive activity first manifested in one rat on the fourth day 
of injection. Abbreviated as (C) in the table, convulsive activity subsequently 
appeared in 2 out of 6 rats (33.33%) on dosing day 5. Additionally, no animals had 
convulsions on the sixth day of injection while arrhythmias were apparent in 83.33% 
of the animals. Hence, the cardiac rhythm aberrations arose before development of 
tonic-clonic convulsions and were independent of the convulsive activity (Table 
3.10).  
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Table 3.10 Frequency of cardiac arrhythmias in rats injected daily with 0.4 LD50 VX  
 
      Arrhythmias       
 DD1 DD2 DD3 DD4 DD5 DD6 DD7 DD8 DD8d1 DD8d2 DD8d3 DD8d4 DD8d5 
Rat 1 - - - Yes          
Rat 2 - Yes Yes Yes          
Rat 3 - Yes Yes Yes Yes Yes Yes (C) Yes (C) Yes      
Rat 4 - - - Yes (C) Yes (C) Yes Yes (C) Yes (C) Yes     
Rat 5 - Yes Yes Yes Yes Yes Yes (C) Yes (C) - - - Yes Yes 
Rat 6 Yes - Yes Yes Yes (C) Yes Yes Yes Yes Yes Yes Yes Yes 
Rat 7 - - Yes Yes Yes - Yes Yes (C) - - - - - 
Rat 8 - Yes Yes Yes Yes Yes Yes Yes (C) Yes Yes Yes Yes Yes 
DD represents dosing day. Symbol (-) indicates no arrhythmias; yes: arrhythmias; yes (C): arrhythmias with convulsions. 
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3.4  CREATINE KINASE – MB ACTIVITY  
 
 Creatine kinase – MB (CK-MB), an isoenzyme of creatine kinase that exists 
in the myocardial muscle, is found in elevated levels in the blood following 
myocardial injury (Mair J et al., 1991). Three groups of rats were challenged with 
different doses of VX (s.c.). Blood was drawn from the rats prior to exposure and 7 
days post exposure to determine CK-MB activity at baseline and after VX exposure. 
The first group of rats was injected daily for two weeks with 0.6 LD50 VX while the 
second group received 0.4 LD50 VX injections for two weeks. The Monday to Friday 
injection regime was used for both groups of rats. Rats in the third group were each 
administered with a single dose of 1 LD50 VX. No chronic dosing was employed in 
this high dosage group to ensure survival of the animals.  
 
 Five out of ten animals survived the chronic 0.6 LD50 VX injections at the end 
of the two weeks while no animals died from the repeated 0.4 LD50 VX injections. 
The survival rate for the 1 LD50 VX group was 6 out of 10 rats. As shown in Table 
3.11 are averaged CK-MB enzyme activities of the rats in the three groups at baseline 
and after VX challenge. In the 0.6 LD50 VX group, CK-MB activities in all rats was 
elevated by 100% from baseline value of 0.1 ± 0 µg/l to 0.2 ± 0 µg/l 7 days after the 
last injection. However, CK-MB values of the rats in the 0.4 LD50 VX group were 
unchanged before and after the chronic injections. The results were similar to the 
control rats which were given saline injections. Although mean basal CK-MB activity 
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in the 1 LD50 VX group increased slightly from 0.150 ± 0.034 µg/l to 0.167 ± 0.033 
µg/l, statistical study showed the difference to be statistically insignificant. 
 
 
Table 3.11 CK-MB enzyme activities before and after VX exposure 
 





0.6 LD50 (n = 5) 0.1 ± 0 0.2 ± 0*** 
0.4 LD50 (n = 10) 0.1 ± 0 0.1 ± 0 
1 LD50 (n = 6) 0.150 ± 0.034 0.167 ± 0.033 
Controls (n = 6) 0.1 ± 0 0.1 ± 0 
 Values represent means ± SEM. 

















































CHAPTER FOUR DISCUSSION AND CONCLUSION 
 
4.1 HISTOPATHOLOGICAL FINDINGS IN ACUTE AND CHRONIC VX 
POISONING  
 
 Light microscopic studies carried out on various organs including the heart, 
kidney, skeletal muscle, lungs and liver of VX-challenged rats revealed VX 
specifically targeted cardiac muscles and produced characteristic cardiac damage. 
Similar to other nerve agent reports (Singer et al., 1987; McDonough et al., 1995; 
Britt JO Jr et al., 2000), cardiomyopathy predominated in the interventricular septum, 
papillary muscles and the left ventricular walls. Typical myocardial injuries included 
multifocal areas of inflammatory mononuclear cellular infiltration and cardiac 
myofibre necrosis. Interstitial deposition of necrotic debris and muscle fibre 
degeneration were consistently produced as well.  
 
 As a result of the usage of high doses of nerve agent in most studies, treatment 
drugs such as anticholinergics, oximes and anticonvulsants were given to sustain the 
lives of the animals. Hence, the possibility of cardiac lesions being altered in form or 
be reduced in severity by the treatments could not be ruled out. Through two acute 
VX studies, the first which involved administration of  pretreatment drug 
pyridostigmine bromide, anti-cholinergic atropine and oxime 2-PAM together with 
1.6 LD50 VX and the second 1 LD50 VX experiment where no treatment drugs were 
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given, it was concluded that the medications did not interfere with the physical 
manifestation of the cardiac injuries.   
In this study, acute 1 LD50 VX experiment demonstrated minimal to mild 
morphological changes in the kidneys and skeletal muscles of intoxicated animals 
with histologic injuries more obvious in the former. Although the histopathological 
damages were not as distinct and apparent as that in the cardiac muscles, the 
morphological changes were reproducible in the intoxicated animals. The skeletal 
muscle damage findings were in agreement with an acute soman study by Britt JO Jr 
et al. (2000) where skeletal muscle lesions such as areas of myonecrosis and cellular 
infiltration were reported to be minimal to mild in severity. Noteworthy as well was 
that treatment drugs given to the 1.6 LD50 VX-challenged rats appeared to reduce the 
inflammatory changes in the kidneys and skeletal muscles. Thus, treatments seemed 
to protect against renal and skeletal muscle damages but not myocardial injuries after 
VX exposure.  
 In the acute 1 LD50 VX study, time profile analysis showed that 
histopathologic emergence of cardiac damage started as early as 24 hours post 
exposure and was evident up to 5 days after exposure. Reparation of the cardiac 
lesions began on day 9 post intoxication and cardiomyopathy was not detected 14 
days post injection. Renal and skeletal muscle damages followed a similar pattern of 
emergence and resolution of histopathological changes. 
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 High convulsive doses of nerve agent (1 LD50 and above) were used in most 
studies to demonstrate the presence of cardiomyopathy (Singer et al., 1987; 
McDonough et al., 1995; Britt JO Jr et al., 2000). The present study showed that 
exposure to chronic non-convulsive, low levels of VX in rats caused cardiac lesions 
as well, a novel finding in the area of nerve agent research. The distribution and form 
of cardiac pathology observed in the chronic low dose-challenged rats were similar to 
that seen in the acute high dose nerve agent challenges both in this present study as 
well as other reports (Singer et al., 1987; McDonough et al., 1995; Britt JO Jr et al., 
2000). Cardiomyopathy observed in the animals which were chronically dosed with 
low levels of VX largely consisted of multifocal inflammatory polymorphonuclear 
cell infiltration and myonecrosis that concentrated in the left ventricular walls and 
interventricular septum, pathological changes that were distinctive of severe nerve 
agent poisoning. Hence although the animals subjected to chronic low level 
intoxication may not show severe symptoms of nerve agent poisoning, such low dose 
exposure can in fact produce significant myocardial damages similar to that in cases 
of high dose exposures.  
 
 In addition, histopathological results also revealed that the severity of cardiac 
damage increased with the quantity of VX administered. Evaluation of the two acute 
VX intoxication studies showed that cardiac lesions were evidently greater in 
incidence and intensity in rats which received 1.6 LD50 VX compared to rats which 
were challenged with 1 LD50 VX. This finding was further supported by the chronic 
0.4 LD50 VX experiment where cardiomyopathy was more distinct and severe in rats 
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which received more injections. Therefore the conclusion that toxic effects of VX 
were cumulative upon repeated VX challenges could be made. Moreover, the clinical 
signs and symptoms of poisoning observed in the intoxicated rats intensified with the 
daily VX doses. Similar progression and aggravation of toxic signs of intoxication 
was reported in guinea pigs subjected to low dose, long-term exposure to VX, sarin 
and soman (Atchison et al., 2004). 
 
 Another valuable discovery was made during the clinical observation of signs 
and symptoms of poisoning upon chronic 0.4 LD50 VX injection and cardiac 
histological investigation. The detection of cardiomyopathy in 50% of non-
convulsing animals that had been dosed for 4 days revealed that severe intoxication 
was not necessary for development of cardiac injury. Since development of 
myocardial damage began prior to the manifestation of severe signs of poisoning, 
monitoring of clinical symptoms of intoxication in VX-poisoned patients alone might 
not be very useful in ascertaining the presence of heart injury. 
 
 Laboratory results in the present study showed that CK-MB enzyme as a 
biomarker of myocardial injury is greatly elevated in cases of severe VX poisoning 
and therefore can serve as a useful indicator of cardiomyopathy in severely 
intoxicated patients. However, the increase in CK-MB levels in incidences of less 
severe VX poisoning is not detectable in state-of-the-art immunoanalysers. 
Nevertheless, technological advancements in immunoanalysers shall be awaited when 
a lower rise in CK-MB activity can be easily detected. 
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Reports have attested substantial correlation between convulsions, neuronal 
damage and myocardial injury and that the myocardial changes were attributed to 
convulsive activity and thereby neurogenic in origin (Singer et al., 1987 and 
Tryphonas and Clement, 1995). Histological examinations in Tryphonas and 
Clement’s study showed that rats dosed with soman had myocardial lesions that 
correlated significantly with central nervous system lesions that had resulted from 
seizure activity. However, several studies have demonstrated that evidence for the 
neurogenic genesis of nerve agent induced - cardiac damage were inadequate 
(McDonough et al., 1995 and Britt JO Jr et al., 2000). The use of anticonvulsants in 
the study by McDonough et al. shed light on the relationship between neuronal and 
cardiac lesions with the finding that cardiomyopathy was not related to the 
effectiveness of the anticonvulsant treatments and appeared at a higher frequency of 
88% compared to the neurological lesions (57%) in the study. Hence weak 
association between cardiac and neuronal damage was established. Investigations 
involving acute and chronic VX exposure in the present study also proved that 
convulsive activity was not likely to have initiated cardiomyopathy. Correlation 
between the clinical manifestation of convulsions with the frequency and severity of 
myocardial injury was unconvincing and weak.  
 
Another hypothesis for cardiotoxicity had been proposed and the proposition 
attributed the genesis of cardiac damage to be cholinergic in nature and that cardiac 
lesions could have been a result of acetylcholine accumulation (McDonough et al., 
1995). It followed that early treatment with anticholinergic drugs was able to protect 
 173 
the animals from cardiotoxicity. However, this study proved anticholinergics to be 
ineffectual in the protection against cardiomyopathy. Despite administration of 
atropine, 1.6 LD50 VX-exposed rats were presented with acute myocardial injuries. 
Furthermore, cardiomyopathy was markedly more acute in 1.6 LD50 VX-challenged 
rats which had less inhibited acetylcholinesterase activity compared to the non-treated 
1 LD50 VX group of rats which presented lower enzyme levels and hence greater 
acetylcholine accumulation. 
Catecholamines, jointly with its oxidative stress metabolites, appeared to be 
responsible for the development of cardiotoxicity (Behonick et al., 2001). Elevated 
levels of catecholamines in circulation, elicited by stressful stimuli, were meant to 
instigate effects to aid in the cardiovascular system and overall energy needs of the 
body in a typical ‘fight or flight’ situation. However, prolonged circulation of the 
catecholamines in the body resulted in detrimental effects, particularly on the heart. 
Exogenous administration or endogenous release of high levels of catecholamines had 
been shown to produce myocardial necrosis in animals (Meerson et al., 1982; Rona, 
1985). However, the pharmacological and physiological changes associated with 
catecholamine administration in animals may not be the only reason for myocardial 
damage. Since catecholamines were rapidly oxidised, it had been proposed that 
oxidative metabolites of catecholamines, collectively known as aminochromes, 
instead of adrenaline or noradrenaline per se, were biochemical mediators of 
cardiotoxicity as well (Yates and Dhalla, 1975; Dhalla et al., 1992).  
 174 
Several possible mechanisms through which increased concentrations of 
catecholamines could bring about cardiotoxicity have been proposed (Behonick et al., 
2001). In summary, hypoxia, hemodynamic modifications, decreased coronary blood 
flow, metabolic changes, membrane permeability alterations resulting in electrolyte 
imbalances and disturbances in calcium homeostasis leading to overloading of 
intracellular levels of calcium ions were suggested as contributory factors to 
cardiotoxicity. Most of the suggested mechanisms attributed cardiac myofibre 
necrosis to the deficit of energy supply that was essential for crucial cellular 
processes maintenance. In addition, inadequacy of hemodynamic mechanisms such as 
alterations in coronary vascular resistance and coronary blood supply inefficiency 
might have produced ischemic conditions, paving the way to cardiac cell necrosis. 
The decreased coronary blood flow on top of increased coronary vascular resistance 
could also lead to eventual coronary spasm, which consecutively triggered cardiac 
arrhythmias and infarction (Behonick et al., 2001). Reduction in mean arterial 
pressure in dogs (Robineau and Guittin, 1987b) as well as marked hypotension in 
rabbits (Preston and Heath, 1972) upon subcutaneous VX administration had indeed 
been reported. Thus, the proposed catecholamine-initiated mechanism through which 
eventually arrhythmia develops is indeed plausible. Oxidative stress elements such as 
free radicals and aminochromes were postulated to work in concert with 
catecholamines in the initiation of cardiotoxicity (Dhalla et al., 1987).  Evidence 
supporting catecholamine- and aminochrome- induced cardiotoxicity in nerve agent 
poisoning was presented by Tryphonas and coworkers (1996) where myocardial 
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damage brought about by soman intoxication was shown to strongly resemble 
catecholamine-induced cardiac injury at the ultrastructural level.  
 
4.2 ELECTROCARDIOGRAPHICAL CHANGES IN ACUTE HIGH 
DOSAGE AND CHRONIC LOW DOSAGE VX CHALLENGES  
 
Electrocardiographic recordings were performed separately in two groups of 
rats which received different VX dosing regimens: (1) acute single exposure to 1 
LD50; (2) chronic daily 0.4 LD50 VX injections for 8 days. Acute 1 LD50 VX exposure 
investigations produced results that tied in with the current literature on ECG findings 
in acute nerve agent and organophosphorus insecticide poisoning (Ludomirsky et al., 
1982; Robineau, 1987a). Intense increase in parasympathetic tone which manifested 
as sinus bradycardia, AV conduction disturbances and arrhythmias was revealed in 
the high dosage VX-challenged animals in this study. Instability in AV conduction 
pathways presented in the form of first- and second- degree AV blocks were detected 
as early as 21.7 ± 2.8 min post injection. Series of short-long ECG cycles that 
occurred in succession to extreme prolongations were detected repeatedly. Malignant 
torsades de pointes (TdP) ventricular tachycardia followed the cardiac arrhythmias. 
Parallel to QTc interval prolongation reported in nerve agent sarin and soman 
intoxication (Abraham et al., 2001; Allon et al., 2005) and organophosphorus 
insecticide poisoning (Saadeh et al., 1997; Karki et al., 2004), QTc interval 
prolongation was discernible in the VX-exposed rats up to 120 min post injection. 
Additionally, distinct lengthening of the PR segment was revealed for 120 min 
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following injection. Impaired conduction through the AV node has been documented 
as a common cause for PR interval prolongation (Conover, 1996), thus justifying the 
occurrence of AV blocks in the animals in the present study. First-degree AV blocks 
had been reported in 1 LD50 VX-challenged beagle dogs which exhibited PR segment 
lengthening in the ECG traces (Robineau and Guittin, 1987b). It is certain that VX 
poisoning can produce disturbances in atrioventricular conduction. 
 
Due to technical limitations in ECG devices, ECG investigations in 
organophosphate compounds intoxication animal studies hitherto either used 
anesthetised animals or were designed as a one-time measurement where the animals 
were sacrificed after the procedure. Constraints on follow-up recordings after 
exposure were present for the latter. In the former case, anaesthetic procedure was 
speculated to have caused interference in cardiac rhythm as cardiac abnormalities had 
been described in anesthetised control animals (Robineau, 1987a). The use of ECG 
implants in this study facilitated the continual monitoring of ECG changes in 
conscious animals for days after VX challenge. Cardiac arrhythmias including second 
degree AV blocks, short-long ECG cycles and immense sustained prolongations 
between ECG waveforms were reproducible up to 14 days post 1 LD50 VX exposure. 
Analysis of the ECG traces revealed evident extension of QTc duration for as long as 
14 days following intoxication. These results are consistent with reports of accidental 
human exposure showing QT segment prolongation for a period of duration of 2 to 3 
weeks (Chuang et al., 1996; Allon et al., 2005). In addition, Abraham and coworkers 
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had reported QTc prolongation in rats for up to 3 months post acute 0.9 LD50 sarin or 
soman exposures (Abraham et al., 2001).  
 
 The present study investigated the presence of cardiotoxicity in chronic 
exposure to low levels of VX, an area of research where not much has been reported 
so far. Cardiac rhythm disturbances emerged in 50% of the rats by dosing day 2 after 
administration of the second 0.4 LD50 VX dose. The proportion exhibiting cardiac 
arrhythmias grew to 100% by the fourth day of injection. Subsequently, the rats 
exhibited recurrent cardiac rhythm irregularities up till the last day of injection (i.e. 
dosing day 8). Cardiac abnormalities observed in the chronically dosed rats included 
sinus bradycardia, first- and second-degree AV blocks, short-long ECG cycles, 
extreme pauses between QRS complexes as well as significant QTc and PR interval 
prolongation. The evidence further corroborated the conclusion drawn from 
histopathological and clinical observations, that toxic effects of VX are cumulative 
and that chronic low level VX exposure eventuates in cardiotoxicity. More 
importantly, occurrence of the cardiac rhythm aberrations arose before appearance of 
specific symptoms of intoxication (i.e. tonic-clonic convulsions). This is the first 
report demonstrating cardiac arrhythmias in animals displaying minimal signs of 
poisoning in the area of nerve agent research as ECG studies of nerve agent have only 
used convulsive doses of nerve agent i.e. greater than 0.5 LD50 to date (Robineau, 
1987a; Robineau, 1987b). This data verified the proposition that cardiotoxicity arising 
from VX intoxication is independent of convulsive activity and is a disparate entity 
distinct from neurotoxicity.  
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 Extension of QTc duration and arrhythmias were sustained in the intoxicated 
rats up till 5 days after the last injection. This demonstrated that akin to acute high 
dosage VX intoxication, cardiotoxicity arising from repeated low dose VX exposure 
is long-standing. Consequential adverse repercussions of lengthened repolarisation 
phase of the ventricular action potential manifested as QTc prolongation is clinically 
significant as it could generate the development of polymorphic ventricular 
tachycardia and delayed sudden cardiac death (Ludomirsky et al., 1982; Mancuso et 
al., 2004). Poor prognosis such as higher respiratory failure incidence, frequency of 
ventricular premature contraction and mortality rate has also been reported in 
organophosphate-poisoned patients demonstrating QTc prolongation (Chuang et al., 
1996; Grmec et al., 2004). Hence, the incessant QTc lengthening detected post acute 
and chronic VX challenge in this present study suggests the necessity for continual 





1. Histopathological changes in various organs of VX-challenged rats had been 
investigated in high level acute and low level chronic poisoning. Results 
revealed VX to specifically instigate myocardial damage and produce 
distinctive myofibre necrosis and inflammatory mononuclear cellular 
infiltration. This study also demonstrated that cardiomyopathy was 
exacerbated with higher doses of VX. 
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2. By a combination of light microscopic study and ECG monitoring, chronic 
low dose VX exposure was demonstrated to precipitate cardiotoxicity in the 
form of cardiomyopathy and cardiac arrhythmias. Toxic effects of VX can 
therefore be deduced as cumulative. Appearance of myocardial injury 
surfaced after dosing day 4 and became more evident after dosing day 8. 
However, arrhythmias manifested as early as the second day of injection.   
3. Through systematic comparison between severe symptoms of intoxication (i.e. 
tonic-clonic convulsions with histopathological changes in the cardiac 
muscle), both 0.4 LD50 and 1 LD50 VX experiments showed that 
cardiotoxicity is not related to convulsive activity and therefore not 
neurogenic in origin. This proposition is further supported 
electrophysiologically with the observation that cardiac arrhythmia and QTc 
prolongation in the chronic 0.4 LD50 poisoned animals arose prior to 
manifestation of convulsions.  
4. Both high dose acute and low dose repeated VX exposure produced long-
lasting irregularities in cardiac rhythm such as short-long ECG cycles and 
QTc prolongations. The rhythm aberrations were reproducible up to 14 days 
post 1 LD50 VX injection. 
5. Anticholinergic drug atropine was administrated with 1.6 LD50 VX in acute 
intoxication and the severe myocardial injury observed in the rats invalidates 
the hypothesis that VX-induced cardiomyopathy is a result of overstimulation 
by acetylcholine accumulation and that anticholinergic treatment in VX 
exposure protects from myocardial damage. Moreover, acetylcholinesterase 
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assays showed that non-treated 1 LD50 VX-challenged animals presented with 
less severe myocardial injury had more inhibited acetylcholinesterase activity 
compared to atropine-treated 1.6 LD50 VX-exposed rats which possessed less 
inhibited acetylcholinesterase activity. 
 
4.4 DIRECTIONS FOR FUTURE RESEARCH 
 
1. Mechanisms by which organophosphates induce cardiotoxicity deserve further 
investigations. The present study has shown that the genesis of cardiac lesions 
and ECG complications from VX exposure do not originate from neurogenic 
cause nor are due to acetylcholine accumulation. Catecholamines and its 
oxidative derivatives (aminochromes) remain very feasible candidates as 
genuine biochemical initiators of cardiotoxicity. Catecholamine assays could 
be incorporated in toxicology tests to detect the level of plasma noradrenaline 
and adrenaline as well as aminochromes in the circulation to determine if a 
correlation between cardiotoxicity and elevated catecholamine and 
aminochrome levels exists.  
2. Chronic low level 0.4 LD50 VX exposure giving rise to cardiotoxicity has 
been demonstrated in this study. ECG and histological studies involving 
chronic challenges to lower concentrations of nerve agent can be designed to 
establish the maximally tolerated or no-adverse-effects-level dose where toxic 
effects on the heart will not be observed. The information will be valuable to 
incident responders of chemical warfare agent attacks for the demarcation of 
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safety zones around a nerve agent incident site and for subsequent reopening 
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